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Colon cancers harbor a variety of mutations that result in uncontrolled proliferation and 
suppression of apoptotic pathways. The initial objective of our work was to understand how 
colon cancer cells survive their inflammatory micro-environment, including high levels of TNF 
and other death ligands.  Towards this goal, we identified a series of mitotically acting 
piperazine-based compounds that sensitized colon cancer cells to TNF-dependent apoptosis. The 
most potent of these compounds, 1-(3-chlorophenyl)-4-(2-ethoxybenzoyl)piperazine or AK301, 
arrested cells in a mitotic state (EC50 ≈ 115 nM) in which the TNF receptor was efficiently 
coupled to caspase-8 activation. Our structure-activity relationship studies predicted AK301 
binding to β-tubulin in a novel orientation that reduced the rate of tubulin polymerization. These 
data suggested that targeting mitosis may be an effective approach for sensitizing cancer cells to 
their inflammatory microenvironment. Further study of the activity of AK301 showed that p53-
normal colon cancer cells efficiently underwent apoptosis in the absence of death ligands 
following release from their mitotic arrest. Study of this effect indicated that AK301-treated cells 
showed high levels of ATM signaling during mitotic arrest and exit from mitosis, following 
compound withdrawal, resulted in a p53-dependent apoptosis. Interestingly, the apoptotic 
activity of AK301 was more apparent in APC mutant cells, suggesting that AK301 exacerbated 
the mitotic defects associated with an APC mutation. This work details the identification and 
structure-activity relationship studies of a new class of small molecule compounds and explores 
their anti-mitotic activity and provides a paradigm for exploiting molecular alterations in mutated 
cells. These findings could serve as a basis for the development of agents that target the 
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molecular alterations in mutated colon cancer cells and augment the apoptotic actions of their 
inflammatory microenvironment, for robust activation of apoptotic signaling. Understanding the 
mechanisms cancer cells use to suppress apoptosis may ultimately facilitate in the development 
of novel approaches to colon cancer treatment and prevention. 
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CHAPTER 1 
Introduction 
 
1.1. Colorectal cancer – prevalence and significance 
Colorectal cancer is the third most common cancer in the United States with an estimated 
1.3 million people being afflicted in the US alone in 2014 [1, 2]. It is the second leading cause of 
cancer-related deaths in the US, with an estimated 50,000 deaths in 2014 [2]. Periodic colon 
cancer screening and the removal of early polyps and other lesions has been demonstrated to 
reduce the risk of death from colon cancer by up to 53% [3, 4]. Screening exams can also find 
early cancers, which increases the likelihood of survival—five-year survival for patients 
diagnosed with colon cancer at an early stage is 74%, but drops to only 6% for metastatic colon 
cancer [3, 5]. For early (stage 1 lesions), surgery is usually sufficient to cure the disease. Some 
drug combinations, such as FOLFOX, are used along with surgery to treat more advanced colon 
cancers [6]. Unfortunately, these regimens have sere side effects and may not completely 
eliminate colon cancer. 
The U.S. Preventive Services Task Force (USPSTF) recommends regular screening for 
colorectal cancer beginning at age 50, by fecal occult blood testing, sigmoidoscopy, or 
colonoscopy [7]. Patients with familial adenomatous polyposis (FAP), hereditary non-polyposis 
colorectal cancer (HNPCC), or a family history of colon cancer are advised to undergo colon 
cancer screening earlier and more frequently (before the age of 50) [8, 9]. However, even with 
careful screening and treatment, the rate of colon polyp recurrence can be high. After three years, 
almost one third of the patients showing a polyp on an initial screening exam will have already 
developed another; after 5 years, this probability increases to ~50% [10]. These data indicate that 
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some individuals may be advised to undergo examinations even more frequently than every five 
years. These data have also prompted the search for strategies that can reduce the frequency of 
polyp development and progression to more advanced lesions. One such strategy is the use of 
chemopreventive agents. These agents could be administered to high risk individuals to 
complement cancer prevention provided by routine colonoscopy. 
Potential chemopreventive agents for colon cancer are often identified in epidemiological 
studies and then assessed in rodent models and human intervention studies by associating intake 
of a particular agent with reduced colon cancer risk [11-13]. This approach led to the 
identification of NSAIDs as chemopreventive agents for colon cancer [14, 15]. However, such 
studies are time-intensive and costly, and the results of these studies vary greatly based on an 
individual’s diet and lifestyle. An alternative approach to identifying chemopreventive agents 
would be to target aberrant pathways in mutated cells and select compounds that selectively 
induces apoptosis of mutated cells in culture. This approach could utilize specific oncogene and 
kinase inhibitors that selectively target cancer cells. Whether this approach will be safe and 
effective in vivo is not clear. The work in this dissertation focuses on understanding specific 
vulnerabilities of colon cancer cells and their precursors. We envision this knowledge leading to 
a better understanding of apoptotic signaling in colon cancer cells, which may in the long run 
lead to new strategies for treatment and prevention.   
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Table 1.1. Stage-wise five-year survival rates for colon cancer. 
The five-year survival at stage I colon cancer is high; the survival rates reduce dramatically with 
each subsequent stage (with the exception of stage IIIA [16]. 
Stage of colon cancer 5-year relative survival rate 
Stage I 92% 
Stage IIA 87% 
Stage IIB 63% 
Stage IIIA 89% 
Stage IIIB 69% 
Stage IIIC 53% 
Stage IV 11% 
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1.2. Apoptosis versus survival 
Apoptosis is vital for the development and homeostasis of metazoans, whereby damaged 
or infected cells are sacrificed for the integrity of the whole organism [17, 18]. It is component of 
normal cell turnover in tissues and is characterized by distinct morphological changes [18, 19]. 
Apoptosis is a highly coordinated and energy-dependent process with characteristic blebbing of 
the plasma membrane, distinct from other forms of cell death (necrosis and autophagy) [19-21]. 
This is followed by separation of apoptotic bodies by budding [19]. Apoptosis can be induced by 
immune system in response to damaged or diseased cells. However, different cells may respond 
differently to the same stimuli and conditions that invoke apoptosis. Apoptosis is critical for the 
survival of neighboring cells by eliminating damaged or infected cells [19]. Evasion of apoptotic 
signals through suppression of internal regulatory controls is one of the hallmark of cancers [22]. 
Suppression of apoptotic responses in transformed cells facilitates the growth and progression of 
neoplastic lesions [23, 24]. Several apoptotic proteins and pathways have been shown to be 
defective or suppressed in colon cancers, as a result of mutations as well as micro-environmental 
conditions within the lesion [25-28]. 
 
1.2.1. Extrinsic versus intrinsic apoptosis 
In mammalian cells, apoptosis can be subdivided into two categories – extrinsic and 
intrinsic apoptosis, depending on the origin of the death stimulus [19]. Extrinsic apoptosis is 
mediated by the death receptor/ligand coupling of the tumor necrosis factor receptor (TNFR) 
superfamily on the cell surface, such as TNFR1/TNF (TRADD), TRAIL/TRAIL-R (DR4 and 
DR5), and Fas/FasL (FADD) . Upon receptor-ligand complex formation, the death receptors can 
initiate signaling via receptor oligomerization. This results in recruitment of adaptor proteins and 
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activation of a cascade of caspases that culminates in the final demise of a cell [19, 27] (Figure 
1.1). Suppression of this pathway results in aberrant growth and survival signaling, leading to 
tumorigenesis [18, 26, 29]. Intrinsic apoptosis, on the other hand, is triggered in response to a 
wide variety of intracellular death stimuli, such as DNA damage and oncogene activation [19, 
27]. Intrinsic apoptosis is distinct from extrinsic apoptosis not only with respect to the death 
stimulus, but also in the mechanisms that carry out apoptosis. The intrinsic pathway is mediated 
by mitochondria; several proteins, including cytochrome c, are released from the mitochondrial 
intermembrane space. Cytochrome c activates and binds to APAF1, which allows for the 
formation of apoptosome and activation of caspase-9 and other downstream effector caspases 
[19] (Figure 1.1). It is important to note that even though the two apoptotic pathways operate by 
distinct mechanisms, they can crosstalk. For instance, caspase-8 (an extrinsic initiator caspase) 
can mediate the cleavage and activation of BID, a pro-apoptotic mitochondrial BCL2 family 
protein, which triggers the release of mitochondrial proteins and the activation of intrinsic 
apoptosis [18, 19]. 
 
1.2.2. Role of caspases in apoptosis and their regulation 
Cysteine aspartate-directed proteases (caspases), a conserved family of enzymes, are 
central to the process of apoptosis [30, 31]. Typically, activation of caspases is a regulated 
process and can be divided into two classes – initiator or apical caspases (caspase-8 and -10) and 
effector or executioner caspases (caspase-3 and -6). Initiator caspases are activated by 
recruitment to the adaptor proteins and death receptor-ligand complex at the cell surface. Initiator 
caspases, in turn, activate effector caspases, which work to cleave cellular proteins [31, 32]. All 
eukaryotic caspases are produced as inactive zymogens and have to undergo proteolytic cleavage 
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during apoptosis [31]. Caspase activation is tightly regulated at different levels in order to illicit a 
fine-tuned response to a death signal and to avoid inadvertent cell death. First, caspases are 
subject to transcription regulation and post-translational modifications. For instance, mRNA 
levels of caspase-2 are regulated in a p53/p21-dependent manner and are upregulated only in the 
case of DNA damage [33]. Similarly, previous studies have shown that caspase-8 is 
phosphorylated by a number of serine/threonine and tyrosine kinases (including Cyclin B/Cdk1 
and p38 MAPK) that have been linked with the inhibition of caspase-8 cleavage and activation 
[33, 34]. Second, caspase activation, especially in the extrinsic pathway, strictly requires the 
recruitment of procaspases to active death signaling complexes at the cell surface (e.g., 
procaspase-8 recruitment by adaptor proteins bound to TNF/TNFR1 death signaling complex) 
[34, 35]. Third, caspase activation is finely regulated through a cascade of initiator and effector 
caspases to prevent inadvertent apoptosis [30, 33]. Fourth, cell survival and apoptosis are 
regulated by several intermediary proteins, such as c-FLIP that compete with procaspases for 
binding to death inducing silencing complex (DISC), thereby preventing caspase activation and 
apoptosis [33, 35]. Lastly, the conserved inhibitor of apoptosis (IAP) family of proteins can 
potently inhibit the activity of caspases and can degrade them through ubiquitination-mediated 
proteasome pathway [36-38]. 
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Figure 1.1. Schematic of extrinsic and intrinsic apoptosis. 
Extrinsic apoptosis is induced by coupling of death receptors with their ligands at the cell 
surface. The signal is then transduced to the inside of the cell via several adaptor proteins that are 
recruited by the death receptors. This initiates recruitment and activation of caspase-8 (an 
initiator caspase), which leads to the activation of caspase-3 (an effector caspase). The activation 
of caspases is repressed by anti-apoptotic proteins, such as IAPs and FLIP (shown as rectangles). 
On the other hand, intrinsic apoptosis initiates with activation of pro-apoptotic Bcl family of 
proteins (e.g., BID), releasing cytochrome c and activating caspase-9. Similar to anti-apoptotic 
signaling in extrinsic apoptosis, caspase-9 activation can be repressed by XIAP. There is 
crosstalk between extrinsic and intrinsic apoptotic pathways as indicated.  
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1.2.3. Apoptosis and colorectal cancer 
Dysregulation of apoptosis leads to a variety of human diseases, such as autoimmune 
diseases, neurodegenerative disorders, and is a hallmark of cancer [19, 39]. While apoptosis is 
essential to homeostasis of the colonic epithelium, abnormalities in apoptotic response can 
contribute to the pathogenesis of colorectal cancer and resistance to chemotherapeutic agents and 
radiation therapy [27]. Thus, there is great interest in understanding how colorectal cancer cells 
evade apoptosis and transition to a more uncontrolled proliferation. Since apoptosis is an 
important mechanism of tumor suppression, there are strong selective pressures to disable 
apoptosis in cancer cells, with most of the mutations targeting pathways leading into apoptosis, 
rather than the apoptotic machinery itself. There are two general mechanisms by which apoptosis 
is suppressed in colon cancers: (1) through the mutation of genes that mediate apoptotic 
signaling and apoptosis, and (2) through the establishment of a micro-environment that 
stimulates survival pathways.  
Colon cancers harbor mutations that suppress apoptotic signaling or apoptotic execution. 
Most common of these are mutations of p53 tumor suppressor gene, TGFβ, PTEN, caspase-8, 
and SMAD4 [40-45]. For instance, p53 is found to be mutated in about 60 percent of colorectal 
cancers and about 15 percent of the colorectal cancers harbor caspase-8 mutations [40]. 
Mutations of p53, SMAD4, and PTEN suppress apoptotic signaling [46], mutations in TGFβ1 
promote proliferation and survival [42, 47], and mutations in caspase-8 inactivate the apoptotic 
machinery [43]. In addition, activating mutations of receptor tyrosine kinase (RTK) as well as 
oncogenes in the MEK/ERK pathway (Kras and Braf) signal for cell survival and proliferation 
[48-50]. In addition to genetic mutations, colon cancer cells also take advantage of the 
inflammatory cytokines in their microenvironment by upregulating pro-survival and proliferation 
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signaling, while suppressing apoptosis [51, 52]. For example, coupling of TNF to TNFR1 can 
mediate NF-κB activation, which targets the transcription of genes involved in cell survival and 
proliferation [53]. However, as previously noted, TNF/TNFR1 coupling can also result in 
caspase-8 activation [34, 54]; cancer cells circumvent this by increasing the cell surface 
expression of TNFR2, which exclusively signals for NF-κB activation [55, 56] (Figure 1.2). 
Thus, cancer cells suppress apoptotic signaling through genetic mutations and by using their 
micro-environment for enhanced survival signaling. 
In summary, induction of apoptosis is one of the major mechanisms of tumor suppression 
and elimination of mutated cells. However, cancer cells develop various mechanisms to evade 
apoptosis. Moreover, cancer cells upregulate survival pathways to increase the likelihood of their 
survival and proliferation. Understanding genetic alterations and molecular events that help 
tumor cells evade apoptosis would establish a paradigm to explain the association between 
alterations in cancer cells, drug resistance, and evasion of apoptosis. Understanding these 
associations may aid in the development of novel, targeted therapies that can activate apoptotic 
signaling in cancer cells and may ultimately help in cancer treatment and prevention. 
 
  
10 
 
Figure 1.2. Schematic of TNFR1-mediated death and survival signaling. 
TNFR1-TNF coupling can mediate extrinsic apoptotic response as well as survival signaling 
through NF-κB activation. Activation of the NF-κB transcription factor results in the 
transcription of survival genes. Activation of survival signaling, in turn, suppresses cellular 
apoptotic signaling. Conversely, activation of apoptosis suppresses cell survival signaling. On 
the other hand, TNFR2-TNF coupling exclusively signals for cell survival via NF-κB activation, 
leading to enhanced cell survival and suppressed apoptosis. 
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CHAPTER 2 
Identification of novel compounds that enhance colon cancer cell sensitivity to 
inflammatory apoptotic ligands 
 
2.1. Abstract 
Immune and inflammatory death ligands expressed within neoplastic tissue could 
potentially target apoptosis to transformed cells. To develop approaches that accentuate the anti-
cancer potential of the inflammatory response, the ChemBridge DIVERSetTM library was 
screened for compounds that accentuated apoptosis in a strictly TNF-dependent manner. We 
identified a number of novel compounds with this activity, the most active of these, AK3 and 
AK10, sensitized colon cancer cells to TNF at 0.5 μM and 2 μM, respectively, without inducing 
apoptosis on their own. The activity of these compounds was structure-dependent and general, as 
they accentuated cell death by TNF or Fas ligation in multiple colon cancer cell lines. Both AK3 
and AK10 arrested cells in mitosis, with live cell imaging indicating that mitotically arrested 
cells were the source of apoptotic bodies. AK3 accentuated caspase-8 and caspase-9 activation 
with little effect on NF-κB target gene activation. Enhanced caspase activation corresponded to 
an increased expression of TNFR1 on the cell surface. To determine the general interplay 
between mitotic arrest and TNF sensitivity, aurora kinase (MLN8054 and MLN8237) and PLK1 
(BI2536) inhibitors were tested for their ability to sensitize cells to TNF. PLK1 inhibition was 
particularly effective and influenced TNFR1 surface presentation and caspase cleavage like 
AK3, even though it arrested mitosis at an earlier stage. We propose that AK3 and AK10 
represent a new class of mitotic inhibitor and that selected mitotic inhibitors may be useful for 
treating colon cancers or earlier lesions that have a high level of inflammatory cell infiltrate. 
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2.2. Introduction 
Inflammation can play a central role in cancer promotion in many tissues, one of the best 
documented being the colon. Extensive ulcerative colitis (UC) has been associated with a 
significant increase in colon cancer development, and managing inflammation with 5-ASA 
decreases this risk [57, 58]. Inflammation may also contribute to the development of sporadic 
colon cancer; nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen can 
decrease cancer risk in the population at large by close to 50% [59-61]. The interaction between 
inflammatory signaling and cancer may continue through late stages of the disease, as most 
cancers maintain elevated levels of TNF, IL6 and other inflammatory mediators [51, 62-65]. The 
role of inflammation in colon cancer development is multifaceted and includes the increased 
generation of DNA-reactive molecules, enhanced angiogenesis and activation of the anti-
apoptotic transcription factor NF-κB [63, 65-69]. 
Although inflammation is associated with cancer development, immune and 
inflammatory cells produce a range of molecules with potent death-inducing capabilities that 
have the potential to limit lesion growth. Evidence suggests that early tissue lesions are kept at 
bay by the immune response [70, 71]. Cancers are in fact found to be “immune-edited,” 
consistent with the active elimination of immunogenic cells from the developing lesion [72, 73]. 
In this regard, the adaptive immune response is likely to be anti-tumorigenic. The contribution of 
innate immunity to cancer development is less clear. Generalized inflammation has been 
implicated in cancer promotion [74]. However, the influence of innate immune cells on cancer 
development may be stage-specific. In the case of advanced colon cancer, macrophage density at 
the tumor margin is strongly associated with a better patient outcome, which may result from 
their ability to generate apoptosis-inducing factors [75]. 
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The death-inducing capabilities of immune cells serves as the basis for cancer therapies 
utilizing vaccines or immune stimulants. For example, the inclusion of Aldesleukin and 
granulocyte- macrophage colony-stimulating factor (GM-CSF) with traditional chemotherapeutic 
agents has been shown to improve the outcome of colon cancer patients [76, 77]. Evidence 
suggests that immune stimulants activate both the innate and adaptive arms of the immune 
response to induce lesion regression [78-80]. The anticancer activities of the immune response 
can be counteracted by a range of phenotypic changes in cancer cells. The cell killing actions of 
the adaptive immune response can be mitigated by the decreased expression of MHC molecules 
on cancer cells [81-83]. A more general resistance to immune cell killing may also be achieved 
by the increased expression of anti-apoptotic proteins, such as survivin and other IAPs, by cancer 
cells [84, 85]. To obtain insight into cellular pathways that are associated with an increased 
resistance to immune cells, we screened a compound library for agents that sensitize colon 
cancer cells to TNF induced apoptosis, without affecting cell viability on their own. 
The majority of compounds obtained through this screen worked through a mitotic arrest 
mechanism. We propose that agents that target mitosis may be well-suited for enhancing the 
anticancer actions of the immune and inflammatory response. We also discuss the possibility that 
the mitotic proteins that are frequently upregulated in colon cancers serve (in part) to ensure that 
cancer cells proceed efficiently through mitosis so that they evade elimination by apoptotic 
ligands. 
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2.3. Materials and Methods 
2.3.1. Cell culture 
HT29 and HCT 116 colon cancer cell line were obtained from the American Type 
Culture Collection. These cell lines were cultured in McCoy’s 5A medium with 10% fetal bovine 
serum, non-essential amino acids and antibiotic/antimycotic (Life Technologies). The AJ02-NM0 
cell line was isolated from an AOM-induced tumor from the A/J mouse strain and were cultured 
in RPMI 1640 with Glutamax (Life Technologies) supplemented with 5% (v/v) fetal bovine 
serum (Lonza), 5% (v/v) heat-inactivated horse serum, 1% (v/v) insulin-transferrin-selenium 
(Gibco), 100 mM non-essential amino acids (Invitrogen) and antibioticantimycotic (Life 
Technologies) [86]. The compounds tested were obtained from the ChemBridge DIVERSetTM 
library. BI2536, MLN8054 and MLN8237 were obtained from Selleck Chemicals. Drug 
treatments were performed approximately 24 h after passage for 18 h, unless otherwise indicated. 
TNF was obtained from Pierce Protein Research Productsand the activating Fas antibody (clone 
CH11) was purchased from Millipore. 
 
2.3.2. Caspase-3 activity 
Caspase activity was determined as previously described [87]. Briefly, cells were scraped 
off into a new tube, centrifuged at full speed in a microcentrifuge at 10,000 × g for 5 min and 
washed once with PBS. Pelleted cells were lysed by two rounds of freeze-thaw in lysis buffer 
containing 10 mM TRISHCl (pH 7.5), 0.1 M NaCl, 1 mM EDTA and 0.01% Triton X-100 and 
centrifuged at 10,000 × g for 5 min. The assays were performed on 96-well plates by mixing 50 
ml of cell lysis supernatant with 50 ml of 2× reaction mix [10 mM PIPES (pH 7.4), 2 mM 
EDTA, 0.1% CHAPS, 10 mM DTT] containing 200 nM of the fluorogenic substrate Acetyl-Asp-
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Glu-Val-Asp-7-Amino-4-methylcoumarin (DEVD-AMC; Enzo Life Sciences). The fluorescence 
was quantified using a microplate reader (excitation/ emission 360/460 nm) at the start of the 
reaction and after 30 min. Protein concentrations were determined using CBQCA Protein 
Quantification Kit (Life Technologies). Caspase activity was determined by dividing the change 
in fluorescence after 1 h by the total protein content of the reaction mixture. 
 
2.3.3. Immunoflurorescence microscopy. 
Treated cells cultured on coverslips were fixed with 4% paraformaldehyde or methanol 
and then permeabilized with 0.5% Triton X-100 in PBS. Cells were blocked in 5% serum (in 
PBS) and then incubated for 1 h at room temperature on the shaker with the primary antibody (in 
5% serum) against cleaved caspase-3 (9961, Cell Signaling Technology), phospho-histone H3 
Ser 28 (sc-12927, Santa Cruz Biotechnology) or β-tubulin (E7 monoclonal antibody, 
Developmental Studies Hybridoma Bank). TNFR1 antibody (H-5, Santa Cruz Biotechnology) 
incubation was performed overnight at 4°C. Appropriate secondary antibodies (Jackson 
ImmunoResearch) were used for 45 min incubation. Nuclei were visualized using DAPI (5 
mg/ml in H2O) (D1306, Life Technologies). Coverslips were mounted on slides using ProLong® 
Gold AntiFade Reagent (Life Technologies). Images were acquired using Nikon A1R Confocal 
Microscope (v. 2.11) and NIS-Elements Advanced Research Software (version 3.2). 
Quantification of immunostaining was performed using ImageJ image analysis software 
(http://rsb.info.nih.gov/ij/) as previously described [88]. Following background subtraction, both 
DAPI and immunofluorescent images were converted to binary using the convert to mask 
function. To remove any false positive signal, a binary image of the colocalized points was 
generated using the colocalization plugin of Bourdoncle 
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(http://rsbweb.nih.gov/ij/plugins/colocalization.html). The integrated densities of the total area of 
the colocalized binary image and the corresponding DAPI image were then measured to generate 
staining index. 
 
2.3.4. Time lapse imaging 
HT29 cells stably expressing histone H2B-GFP were used for live cell imaging. Images 
were taken with Nikon A1R Confocal Microscope every 16 min as Z-stacks of 30 images, each 1 
μm apart. Images were restacked using Fiji/ ImageJ (National Institute of Health). 
 
2.3.5. Cell cycle analysis 
HT29 and HCT116 cells were analyzed for DNA content by ethanol fixation and staining 
with propidium iodide as previously described [89]. Floating and adherent cells were combined 
and analyzed by flow cytometry. Adherent cells were harvested using a trypsin-EDTA solution, 
centrifuged together with the floating cells at 100 × g for 5 min and resuspended in 1 ml of cold 
saline GM. Cells were then fixed by adding 3 ml of cold 100% ethanol while gently vortexing 
and stored at -20°C for at least 2 h. Cells were then pelleted and washed once with PBS 
containing 5 mM EDTA. Pelleted cells were stained with 30 μg/ml propidium iodide (Sigma-
Aldrich) and 0.3 mg/ml RNase A in 1 ml PBS solution for 1 h in the dark at RT. The stained 
cells were filtered prior to analysis on FACSCalibur flow cytometer (BD Biosciences) using Cell 
Quest software (BD Biosciences). The data were analyzed using FlowJo (TreeStar Inc.). 
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2.3.6. Western blot 
RIPA buffer was employed for protein extraction and 30 μg of protein was denatured 
under reducing conditions [90, 91]. Proteins were separated on 4–20% gradient gels (Bio-Rad) 
and transferred to nitrocellulose by voltage gradient transfer. The resulting blots were blocked 
with 5% (w/v) non-fat dry milk in PBS + 0.1% (v/v) Tween-20. Specific proteins were detected 
with appropriate antibodies using enhanced chemiluminescence detection (Santa Cruz 
Biotechnology) as recommended by the manufacturer. Immunoblotting antibodies were survivin 
(71G4B7, Cell Signaling Technology), phospho-survivin (Thr34) (D2E11, Cell Signaling 
Technology), cleaved caspase-8 (18C8, Cell Signaling), caspase-9 (human specific, Cell 
Signaling), pro-caspase-8 (8CASP03, Santa Cruz Biotechnology), TNFR1 (H-5, Santa Cruz 
Biotechnology) and β-actin antibody (I-19, Santa Cruz Biotechnology). 
 
2.3.7. RNA quantification 
Total RNA extraction was performed using Trizol reagent (Life Technologies) following 
the manufacture’s instruction. RNA was quantified by reverse transcription and quantitative PCR 
analysis using Taqman reagents (Life Technologies), as previously described [90]. 
 
2.3.8. Compound synthesis 
Starting from commercially available tert-Butyl piperazine-1-carboxylate, a Buchwald 
coupling (palladium cross coupling reaction between an amine and an aryl halide) was 
performed to append the dimethylbenzene ring to the free amine. Deprotection of the carbamate 
was achieved using 20% HCl in methanol. Subsequent amidation using trimethylamine and 
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various acyl chlorides yielded the final compounds that were tested after purification by column 
chromatography and structure validation using proton and carbon NMR. 
 
2.3.9. Statistical analyses 
All results are reported in triplicates as mean ± standard error of mean, unless specified 
otherwise. One-way analysis of variance (ANOVA) was used when comparing two groups with 
Tukey’s post hoc test. For more than two groups, two-way ANOVA was used with Bonferroni 
correction. Significance was calculated at an alpha of 0.05. 
 
2.4. Results 
2.4.1. Compound screen for the induction of TNF sensitivity 
Four hundred compounds from the ChemBridge DIVERSetTM library were assessed for 
their ability to increase the sensitivity of the HT29 colon cancer cell line to TNF-induced 
apoptosis (Figure 2.1A). For this screen, duplicate 96-well plates were generated and treated in 
parallel with 40–50 μM of compound with one of the plates containing 50 ng/ml TNF. After 18 
h, the plates were visually inspected for cell death and cellular extracts were prepared for an 
enzymatic caspase-3 assay (using the DEVD-AMC fluorogenic substrate). From this initial 
screen, six compounds were selected for further analysis, based on the level of caspase activation 
in the presence of TNF. These compounds were retested on HT29 cells, with active caspase-3 
staining employed as a test of apoptosis. Quantification of this staining showed that the six 
compounds identified in the primary screen increased active capsase-3 in HT29 cells in a strictly 
TNF-dependent manner (Figure 2.1B). The structures of these compounds are shown in Figure 
A1. 
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Two of the most active compounds from the screen, AK3 and AK10, were taken for 
further analysis. Figure 2.2A shows their chemical structure; both have a central piperazine 
group with a phenyl and a benzoyl group attached to the two piperizane nitrogens. HT29 cells 
treated with TNF in combination with AK3 or AK10 showed an increase in the proportion of 
cells expressing active caspase-3, with positively staining cells frequently showing an apoptotic 
morphology (Figure 2.2B). A titration of the compounds for activation of caspase-3 (DEVDase) 
in the presence and absence of TNF is shown in Figure 2.2C. Neither AK3 nor AK10 
significantly induced caspase-3 activity on their own, but did so when TNF was present. The 
level of agent required to stimulate apoptosis when TNF was present was in the low micromolar 
range for both AK3 and AK10, with an LD50 of 0.5 μM for AK3 and 2 μM for AK10. 
Since both AK3 and AK10 compounds have a similar chemical structure, we generated a 
number of related compounds to determine whether their TNF sensitizing activity was dependent 
on their structure or whether it was a property inherent to the central piperazine group. The 
compounds synthesized are shown in Figure A2A. Application of these compounds to HT29 
cells in the presence or absence of TNF showed that AK24 had a significantly higher TNF 
sensitizing activity than the other derivatives (Figure A2B). AK24 was, however, significantly 
less potent than AK3, as shown in Figure A2C. These structure-activity studies indicate that the 
activity of the piperazine-based compounds AK3 and AK10 result from specific structural 
elements that most likely function by binding to specific target molecules in the cell. 
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Figure 2.1. Identification of compounds that induce caspase-3 activation in a TNF-
dependent manner. 
(A) Schematic of the strategy employed for screening compounds from ChemBridge 
DIVERSetTM library. HT29 colon cancer cells were treated with 5 µM of test compounds for 18 
h in the presence or absence of TNF (50 ng/ml). Cell lysates were prepared and tested for 
caspase-3 activity using the DEVD-AMC fluorogenic substrate. (B) The compound screen 
identified six compounds that induced caspase-3 activation only in the presence of TNF using a 
DEVDase assay. As a secondary screen, compounds were tested by immunostaining cells using 
an antibody specific for cleaved caspase-3. Images were captured and the fraction of cells 
staining positive for caspase-3 were quantified. AK3 and AK10, two of the most active 
compounds, were selected for further investigation (*P < 0.0001). 
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Figure 2.2. Similarity in structure and TNF-dependent caspase-3 activation between AK3 
and AK10. 
(A) Similar chemical structure of AK3 and AK10. AK3 and AK10 both have a core piperazine 
group substituted with phenyl and benzoyl groups at the two piperazine nitrogens. (B) Increased 
caspase-3 and apoptosis in the combination treatment of AK3 or AK10 with TNF. HT29 cells 
were treated with AK3 or AK10 in the presence or absence of TNF for 18 h. Cells were fixed, 
permeabilized, and stained for active caspase-3. Higher proportion of cells stained for active 
caspase-3 in the combination treatment compared to control or AK3/AK10 treated cells. 
Positively staining cells displayed an apoptotic morphology. Bar, 100 µm. (C) Representative 
dose-response curves of caspase-3 activity with increasing concentrations of AK3 or AK10, in 
the presence or absence of TNF over 18 h.  Significant caspase activation was observed only in 
the combination treatment. The asterisks indicated points where the combination treatment was 
significantly higher than compound or TNF treatment alone (*P < 0.01). LD50s of AK3 and 
AK10 in the presence of TNF were determined to be 0.5 µM and 2.0 µM, respectively. 
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2.4.2. Generality of AK3 and AK10 activity 
To determine the generality of apoptotic sensitization by AK3 and AK10, these 
compounds were tested on the HCT116 colon cancer cell line (Figure 2.3A). HCT116 cells are 
more sensitive to TNF induced apoptosis than HT29 cells (which possibly results from their 
wild-type p53 status). However, AK3 was capable of further enhancing TNF induced caspase 
activation in these cells, whereas AK10 was not. AK3 and AK10 were also tested on a mouse 
colon cancer cell line, AJ02-NM0 cells (a p53-normal cell line derived from an AOM-induced 
colon tumor) [92]. TNF induced caspase-3 activation was stimulated in these cells by both AK3 
and AK10, with AK3 being more potent (Figure 2.3B). Finally, we determined whether AK3 and 
AK10 could stimulate caspase-3 activity induced by the Fas pathway. As shown in Figure 2.3C, 
both AK3 and AK10 stimulated Fas-induced caspase activation, without significantly inducing 
caspase activity on their own. From these data, we conclude that both AK3 and AK10 are 
broadly active on different cell lines and with different death ligands, with AK3 being more 
general in its activity. 
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Figure 2.3. Effect of AK3 and AK10 on other colon cancer cell lines and on Fas-mediated 
cell death. 
(A) TNF was titrated on to HCT116 cells in the presence or absence of 20 µM AK3 or AK10 for 
18 h.  Although these cells are more inherently sensitive to TNF, AK3 significantly increased 
caspase activity as measured by DEVD-AMC cleavage (*P < 0.01). AK10 did not significantly 
increase caspase activation in this cell line. (B) The mouse colon cancer cell line AJ02-NM0 cells 
was treated with AK3 or AK10 and in the presence or absence of murine TNF for 18 h and 
analyzed for caspase activity. Both AK3 and AK10 increased caspase activity in the presence of 
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TNF, but not in its absence (*P < 0.001). AK3 was significantly more effective than AK10 (*P < 
0.001). (C) AK3 and AK10 accentuated caspase activation by Fas ligation of HT29 cells. Cells 
were treated with AK3 or AK10 alone or in combination with an anti-Fas antibody (10 µg/ml) 
for 18 h and analyzed for caspase activation. Although HT29 cells are sensitive to Fas ligation, 
both AK3 and AK10 significantly enhanced caspase activation (*P < 0.001). 
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2.4.3. Mitotic arrest and TNF sensitivity 
A flow cytometric analysis of propidium iodide (PI)-stained cells was performed to 
assess the impact of AK3 and AK10 on the generation of subdiploid cells. Co-treatment of HT29 
cells with either compound in combination with TNF increased the sub-diploid population 
approximately 10-fold (Figure 2.4, right column). Treatment with AK3 or AK10 alone increased 
the fraction of cells in G2/M phase to approximately 70% (Figure 2.4). Interestingly, TNF 
caused a drop in the G2/M population that corresponded with the increased appearance of sub-
diploid cells, suggesting that the G2/M cells were the cells targeted for apoptosis. 
To determine if AK3 and AK10 induced a G2 or M phase arrest, immunofluorescent 
staining for the mitosis marker phospho-histone H3 Ser28 was performed [93, 94]. As shown in 
Figure 2.5A, both compounds induced a high level of phospho-histone H3 staining, consistent 
with a mitotic arrest (Figure 2.5A). Confocal analysis of the arrested cells showed similar mitotic 
structures induced by the compounds: in both cases, chromatin was condensed, but there was no 
congression of the chromosomes on the metaphase plate (Figure 2.5B). In addition, there were 
indications of mitotic spindle assembly, with apparent multiple microtubule organizing centers 
(Figure 5B). Other compounds identified in the screen likewise generated a mitotic arrest, as 
determined by enhanced histone H3 phosphorylation (Figure 2.5C). The induction of a mitotic 
arrest therefore appears to be a common mechanism for TNF sensitization. 
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Figure 2.4. AK3 and AK10 induce a G2/M arrest on their own and sub-diploid cell 
fragments in the presence of TNF. 
HT29 cells treated with AK3 or AK10 in the presence or absence of TNF for 18 h were analyzed 
for DNA content by propidium iodide staining. Flow cytometric analysis of AK3 and AK10 
treated cells showed a shift from G1 to G2/M. In the presence of TNF alone, little change in the 
flow cytometer pattern is observed. Combining TNF with AK3 and AK10 showed a decrease in 
the G2/M peak and the appearance of a sub-diploid population. 
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Figure 2.5. AK3 and AK10 induce prophase arrest with the appearance of multiple 
microtubule organizing centers (MTOCs). 
(A) HT29 cells treated with AK3 and AK10 for 18 h were fixed and stained for phospho-histone 
H3 Serine 28, a marker for chromatin condensation during mitosis. Cells were stained and 
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examined at 20X magnification by epi-fluorescence. (B) AK3 and AK10 arrest cells in prophase 
with multiple MTOCs. AK3- and AK10-treated cells were dual stained for phospho-histone H3 
(green) and β-tubulin (red) to visualize spindle assembly in arrested cells. Confocal imaging 
shows prophase arrested cells with spindles arising from multiple poles. Insets show magnified 
views of the mitotic cells. (C) Many compounds identified in the screen induce mitotic arrest. 
HT29 cells were treated with the indicated compounds at 25 µM and stained for phospho-histone 
H3. Images were captured and the mitotic index was quantified as a ratio of number of cell 
staining positive for histone H3 phosphorylation divided by the total number of cells visualized 
by DAPI staining (*P < 0.0001).  
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The flow cytometer data suggested that the sub-diploid cells in the co-treated cultures 
were derived from the arrested M phase population. To address this issue further, time-lapse 
imaging was performed on HT29 cells expressing a histone H2B-GFP fusion protein. As shown 
in Figure 2.6, cells treated with AK3 arrested in mitosis as indicated by the condensation of 
histone H2B-GFP fluorescence. Moreover, cells displaying condensed chromatin ultimately 
underwent apoptosis when TNF was present, further supporting the sensitivity of mitotically 
arrested cells. 
 
2.4.4. Effect of AK3 on TNF signaling 
Increased sensitivity to TNF-induced apoptosis could arise from an increased signaling 
through the proximal initiator caspase-8, through the suppression of the anti-apoptotic NF-κB 
signaling pathways or through a combination of these effects [95-97]. To assess the potential 
contribution of these pathways to sensitization, we determined the effect of AK3 on TNF-
induced gene activation and caspase-8 and -9 cleavage. As shown in Figure 2.7A, gene 
activation by TNF was largely unaffected by AK3, whereas the activation of the initiator 
caspase-8 and caspase-9 was increased (Figure 2.7B). Cleavage of pro-caspase-8 showed the 
largest fold change; its cleavage was undetectable in cells treated with TNF or AK3 alone, but 
nearly complete when cells were treated with TNF and AK3 for 6 hrs. 
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Figure 2.6. AK3-idnuced mitotically arrested cells undergo apoptosis. 
Time lapse imaging of histone H2B-GFP expressed in HT29 cells. Cells were treated with either 
AK3 (top panel) or AK3 plus TNF (bottom panel). Representative images show chromatin 
condensation in the cells treated with AK3 alone, whereas addition of TNF in combination with 
AK3 increased apoptosis of the mitotic cells. Arrows point to the cells undergoing mitosis (top 
panel and bottom panel, t = 3 h) and/or apoptosis (bottom panel, t = 7 h to t = 9 h). 
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Figure 2.7. Effect of AK3 on gene activation and initiator caspase cleavage by TNF. 
(A) HT29 cells were treated with AK3, TNF or AK3 plus TNF for 4 h. RNA was isolated, 
reverse transcribed, and quantified for expression of TNF, BIRC3, and p21 by real-time PCR. 
TNF activated the expression of the three genes tested relative to control cells (*P < 0.001), and 
there was no significant effect of AK3 on this activation. (B) AK3 enhances the TNF induced 
cleavage of caspase-8 and caspase-9. Cells were treated with TNF for 0, 2, 4, and 6 h in the 
presence and absence of AK3 and lysates were analyzed by immunoblotting with antibodies 
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against full length and cleaved caspase-8 and -9. (C) Protein samples were analyzed for TNFR1 
by immunoblotting. β-actin was used as the loading control.  
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A western blot analysis was performed to determine if AK3 altered the expression of the 
TNF receptor responsible for caspase-8 activation, TNFR1 [98, 99]. Increased caspase-8 
cleavage was not associated with an increased expression of total cellular TNFR1 as determined 
by western blot analysis (Figure 2.7C). In fact, a slight decrease in expression was observed in 
cells following treatment with AK3 or TNF. To determine whether TNFR1 cellular localization 
was altered by AK3, cells were examined by immunofluorescent staining. For this experiment, 
cells were either paraformaldehyde fixed and stained directly for TNFR1 or fixed and 
permeabilized with Triton X-100 prior to immunostaining. This analysis showed that while 
permeabilized cells stained uniformly for TNFR1 expression, non-permeabilized cells showed 
more variable expression (Figure 2.8A). We ascribe these changes in staining to changes in the 
cellular localization of TNFR1, with the staining of non-permeabilized showing receptors 
expressed at or close to the cell surface. A higher magnification view showed that cells in mitosis 
frequently displayed more intense staining than interphase cells under non-permeabilized 
staining conditions (Figure 2.8B). To determine the relative level of TNFR1 strictly on the cell 
surface, cells were transferred to ice and stained directly, without fixation or permeabilization 
(Figure 2.8C). This live cell staining protocol showed a higher level of TNFR1 staining on AK3-
treated cells, with the number of cells staining for TNFR1 increased by approximately five-fold 
(Figure 2.8D). The increased level of cell surface expression of TNFR1 may contribute to the 
observed increase in TNF induced caspase-8 activation. 
 
2.4.5. Mitosis targeting and TNF sensitivity 
A number of pharmacological agents have been developed that can arrest cells in mitosis. 
We tested a number of these agents for their ability to enhance TNF induced caspase activation 
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and apoptosis. As shown in Figure 2.9A, two aurora A kinase inhibitors (MLN8054 and 
MLN8237) and a PLK1 inhibitor (BI2536) were all able to stimulate caspase activation by TNF 
[100-104]. Of these three agents, BI2536 was the most potent for facilitating caspase activation, 
even though they all induced mitotic arrest in approximately 70% of the cells. Cell cycle analysis 
of HT29 cells treated with BI2536 in the presence or absence of TNF showed that the BI2536 
induced a G2/M arrest in approximately 70% of the cells and that inclusion of TNF with BI2536 
increased the sub-diploid population while decreasing the fraction of cells in G2/M arrest (Figure 
2.9B). This result is consistent with apoptosis in the G2/M phase cells being the primary source 
of the sub-diploid cells. The AJ02-NM0 mouse colon cancer cell line was likewise sensitized to 
TNF by BI2536, but less so by the two aurora kinase inhibitors (Figure 2.9C). Figure 2.9D shows 
that BI2536 and AK3 induce a comparable level of TNF induced caspase activity in HT29 cells, 
making them roughly equivalent in effectiveness. These data indicate that mitotic arrest can 
sensitize cells to TNF, but the degree of sensitization can vary depending on the mechanism of 
arrest. 
A critical signaling event that occurs during mitosis linked apoptosis is the 
phosphorylation of the kinetochore-associated passenger protein survivin by Cdk1-Cyclin B 
[105]. Survivin phosphorylation at Thr34 promotes mitotic progression and suppresses apoptosis 
[105, 106]. As shown in Figure 2.10A, AK3 treatment increased survivin phosphorylation, 
indicating that the cells can proceed past Cdk1 activation in mitosis. Interestingly, cells treated 
with AK3 and TNF undergo apoptosis even in the face of increased survivin phosphorylation. 
Figure 10A shows that cells treated with BI2536 have a relatively low level of survivin 
phosphorylation, which is consistent with its activity as a Plk1 inhibitor, which is upstream of 
Cdk1-Cyclin B. This analysis is consistent with BI2536 and AK3 arresting mitosis through 
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distinct mechanisms, even though they can both increase sensitivity to TNF. Like AK3, BI2536 
enhances caspase-8 and caspase-9 cleavage (Figure 2.10B) without reducing the activation of 
TNF target genes (Figure 2.10C). Also like AK3, BI2536 increases the number of cells that 
express high levels of TNFR1 on their surface, suggesting a possible mechanism of action for 
cell sensitization with BI2536 (Figure 2.10D). 
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Figure 2.8. Mitotic cells have a higher expression of TNFR1. 
(A) HT29 cells were treated with AK3 for 16 h and then fixed with PFA. Fixed cells were either 
stained directly with a TNFR1 antibody or were stained following permeabilization with Triton 
X-100. (B) Higher magnification of TNFR1 staining of permeabilized and non-permeabilized 
AK301-treated HT29 cells. All cells show TNFR1 expression following permeabilization, but 
staining is more variable in the absence of Triton X-100 permeabilization (as indicated). Mitotic 
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cells with round morphology and condensed chromatin frequently show elevated TNFR1 
expression. (C) Live cells stained for surface expression of TNFR1. HT29 cells were transferred 
to ice and stained directly for TNFR1 expression. (D) Quantification of the live cells expressing 
TNFR1 on the surface. Images were captured and quantified for the number of cells staining with 
the TNFR1 antibody. Significantly more cells cell stained for surface expression of TNFR1 after 
AK3 treatment (*P < 0.01). 
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Figure 2.9. Effect of kinase inhibitors on TNF sensitivity of colon cancer cells. 
(A) TNF induced caspase-3 activation in the presence of MLN8054, MLN8237 (aurora kinase A 
inhibitors) and BI2536 (PLK1 inhibitor). HT29 cells were treated with the indicated 
concentrations of the inhibitors in the presence or absence of TNF for 18 h and tested for 
caspase-3 activity using DEVD-AMC substrate. BI2536 induced significantly higher level of 
caspase activation than the aurora kinase A inhibitors (*P < 0.01). (B) Cell cycle analysis of 
HT29 cells treated with BI2536 in the presence or absence of TNF. BI2536 at 100 nM induces a 
G2/M arrest, and in combination with TNF, causes the appearance of sub-diploid population. (C) 
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BI2536 enhances TNF induced apoptosis in the mouse AJ02-NM0 colon cancer cell line more 
potently than MLN8054 or MLN8237. AJ02-NM0 cells were treated with the inhibitors in the 
presence or absence of murine TNF for 18 h and tested for caspase activation using the DEVD-
AMC substrate. Inhibitors were used at 0, 125, 250, 500, and 1000 nM (from left to right). 
BI2536 was a significantly more potent sensitizing agent than aurora kinase A inhibitors at all 
concentrations tested (*P < 0.05, **P < 0.01). (D) AK3 and BI2536 induce comparable levels of 
caspase activation in HT29 cells in the presence of TNF. Cells were treated with the indicated 
agents and tested for caspase activation using DEVD-AMC substrate. AK3 and BI2536 in 
combination with TNF induced significantly higher caspase activity than either individual 
treatment (*P < 0.01). 
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Figure 2.10. AK3 enhances caspase-8 and -9 activation without reducing the activation of 
surviving or TNF-targeted genes. 
(A) Influence of AK3 and BI2536 on mitosis-dependent surviving phosphorylation. HT29 cells 
were treated with AK3 or BI2536 in the presence or absence of TNF for 18 h, as indicated. 
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Lysates were analyzed by immunoblotting with antibodies against total surviving and surviving 
phosphorylated at Thr34. β-actin was run as the loading control. (B) Effect of BI2536 on initiator 
caspase cleavage. HT29 cells were treated with TNF for the indicated times in the presence or 
absence of BI2536. Cell lysates were prepared and analyzed caspase-8 and caspase-9 cleavage. 
(C) Effect of BI2536 on gene activation by TNF> HT29 cells were treated with the TNF in the 
presence or absence of BI2536 as indicated. RNA was extracted at 4 h and quantified for 
expression of TNF, BIRC3, and p21 mRNA by reverse transcription/ real-time PCR assay using 
actin as an internal control. The expression levels shown are relative to the untreated control 
cells. TNF activated the expression of the three genes tested relative to control cells (*P < 0.001), 
but there was no significant effect of BI2536 on this activation. (D) Quantification of the live 
cells expressing TNFR1 on the surface. Images were captured and quantified for the number of 
cells staining with the TNFR1 antibody. Significantly more cells stained for surface expression 
of TNFR1 after BI2536 treatment (*P < 0.0.1).  
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2.5. Discussion 
Colon cancers arise in an inflammatory microenvironment and continue to accommodate 
elevated levels of infiltrating immune cells as they progress. Although the suppression of 
inflammation over the long-term is a sensible approach to colon cancer prevention, a 
complementary approach would be to take advantage of the pro-apoptotic signals associated with 
an inflammatory response to target transformed cells for apoptosis. A number of natural and 
pharmacological agents, including NSAIDs, appear to have this ability and have been reported to 
increase cancer cell sensitivity to TNF, TRAIL or Fas ligand, although it is not clear how this 
activity functions in cancer prevention [87, 91, 107-109]. We and others have reported that 
HDAC inhibition is particularly effective at increasing colon cancer cell sensitivity to TNF, Fas 
and TRAIL [87, 110]. This sensitizing activity may account for the reported ability of 
SAHA/Vorinostat to selectively enhance apoptosis in AOM-induced colon tumors and suppress 
their formation and growth [87, 111-113]. It is not clear, however, whether HDAC inhibitors are 
ideal for this purpose since they also cause changes in histone acetylation and gene expression 
systemically. 
To better understand the mechanisms by which cancer cells can be sensitized to the 
inflammatory milieu of a lesion, we screened for compounds that increase TNF induced 
apoptosis of colon cancer cells. Of the 400 compounds screened, 2 of the agents identified AK3 
and AK10, had good potency and were structurally related. Interestingly, these and a number of 
other compounds identified in the apoptosis screen also induced mitotic arrest, with evidence 
pointing to a higher apoptotic rate of mitotically arrested cells. A number of pharmacological 
agents that target mitosis were also found to increase cancer cell sensitivity to TNF, but with 
varying efficacy. For instance, a Plk1 inhibitor (BI2536) was found to function better than two 
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aurora kinase A inhibitors (MLN8054 and MLN8237) at sensitizing cancer cells to TNF induced 
apoptosis, even though they all enforced comparable degrees of mitotic arrest. Compounds 
identified in the library screen likewise showed variations in their ability to induce mitotic arrest 
and sensitize cells to TNF. For example, AK16 was the most potent mitotic arrest agent but not 
the best sensitizing agent. The reason for this variation in efficiency is not clear. Nonetheless, our 
data suggest that selected mitotic inhibitors may effectively target neoplastic lesions because of 
their elevated rate of cell division, their loss of mitotic checkpoints and because they sensitize 
cancer cells to their inflammatory micro-environment. Whether this approach would be feasible 
on its own for clearing lesions from the colonic mucosa will require further study. 
Mobilization of the immune response, whether through vaccination, immune stimulatory 
treatments or inflammatory agents, has long been envisioned as an ideal approach to selectively 
target cancer cells. Tumor cells have been documented to present epitopes that can be recognized 
as foreign by the immune response and that well-considered stimulants can direct immune cells 
to neoplastic lesions. Immune stimulants ideally increase the activity of cytotoxic T cells (CTLs), 
which function through either Fas ligation or release of perforin/granzyme. The Fas system 
becomes particularly important for targeting cancer cells with weak TCR-epitope complexes [72, 
73]. Since tumors are immune-edited for strongly immunogenic epitopes, enhancing Fas-
inducing cell death may be particularly beneficial [114]. We found that both AK3 and AK10 can 
enhance cell death mediated by Fas ligation, suggesting that these or similarly acting agents 
might increase the effectiveness of CTLs. The induction of a strong Th1 response by immune 
stimulants also increases the local concentration of a number of characteristic cytokines, 
including TNF. AK3, AK10 and similarly acting agents might, therefore, facilitate the TNF-
induced cell killing to eliminate cells in the lesion that escape direct CTL detection. 
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In addition to identifying potential drug targets, compound screens can also generate 
molecular probes useful for identifying and studying critical pathways in cancer progression. In 
this regard, the results of our compound screen indicate that mitotic regulators may play an 
important role in helping cancer cells resist death ligands within the inflammatory milieu of a 
neoplastic lesion. Colon cancer cells have long been noted for altered expression of proteins 
involved in mitosis. These proteins include components of the centromeres as well as kinases 
and ubiquitin ligases that regulate mitotic progression [115, 116]. Proteins in this latter group 
include Cyclin B, aurora kinases A and B and CHFR [117-121]. CHFR, which regulates entry of 
cells into prophase is frequently silenced by promoter methylation in colon cancer cells [118]. 
The altered expression of mitotic proteins in colon cancer cells likely contributes to their 
chromosomal instability. However, these changes are also observed in colon cancer cells with a 
mutator phenotype that are chromosomally stable. For example, CHFR silencing is frequently 
associated with MLH1 silencing and a mutator phenotype [122]. We propose that the altered 
expression of mitotic regulators may function in part to facilitate the survival of cells within an 
inflamed tissue environment. This alteration may occur early in cancer development—it has been 
reported that aurora kinase A and Bub1B are overexpressed in preneoplastic mucosa of 
ulcerative colitis patients [123]. Aberrant expression of proteins that promote mitosis may help 
ensure that cells do not arrest at prophase/prometaphase for a prolonged period of time when 
they may be more sensitive to ligand-induced apoptosis. 
The mechanism linking death ligand sensitization and mitosis is not well understood. We 
found that mitotic arrest by AK3 showed enhanced cleavage of the initiator caspase-8 and -9. 
The enhancement of caspase-8 cleavage was, however, more dramatic; little cleavage, if any, 
was observed when cells were treated singly with TNF or AK3, whereas the combination 
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treatment lead to a near complete cleavage. Since TNFR1 is responsible for directing casapse-8 
activation, its expression and cellular localization was analyzed. Although AK3 did not increase 
the overall expression of TNFR1, it did increase its appearance on the cell surface. These results 
suggest that AK3 works in part by increasing the level of TNFR1 on the cell surface, which 
would increase its ability to interact with TNF and form a death inducing complex (either on the 
cell surface or following endosome incorporation). Arresting cells in mitosis with BI2536, 
likewise, increased the expression of TNFR1 on the cell surface. It is somewhat counterintuitive 
that the increased surface expression of TNFR1 would induce caspase-8 cleavage, but not the 
activation of TNF/NF-κB target genes. Although there are a number of explanations for this 
observation, perhaps the most likely is that TNF also activates the expression of the NF-κB 
inhibitory proteins IκBα and p105, which establishes a negative feedback loop for TNF-induced 
gene activation [124]. In contrast, caspase-8 activation is characterized by positive feedback 
loops [125], such that repeated binding and stimulation of the receptor may lead to persistently 
increasing levels of caspase cleavage and death signaling. 
Cell surface expression of TNFR1 on cancer cells was found to be highly variable, even 
under normal growth conditions. The reason for this high level of variability is not known, but 
presumably involves alterations in receptor trafficking through different membrane 
compartments. Relative to interphase cells, mitotic cells displayed elevated levels of TNFR1 
surface expression, such that the overall frequency of surface expression was increased by AK3. 
We hypothesize that cells undergoing mitotic stress due to chromosome or spindle abnormalities 
display more TNFR1 on their surface to facilitate their elimination from the tissue. This may be 
an important checkpoint during cancer development. However, unlike other checkpoint 
pathways, such as those involving increased expression of p16INK4A or p14ARF, this pathway 
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requires that presence of an extracellular death ligand [126]. The role of TNFR1 is colon cancer 
development is consistent with the finding that TNFR1 null mice are more sensitive to tumor 
formation than wild type animals (in the AOM/DSS model) [127]. Although the apoptosis rate in 
normal tissue is not changed in TNFR1 null animals, TNFR1 may reduce cancer risk by inducing 
apoptosis of rare, genetically damaged cells. The extent to which TNFR1 signaling eliminates 
damaged and mitotically arrested cells from the tissue remains to be determined. An interesting 
parallel, however, appears to exist in Drosophila where TNF and TNF receptor homologs Eiger 
and Wegen, respectively, serve to remove damaged cells from developing epithelial tissues 
[128]. 
The two most active compounds identified in our screen contain a piperazine core 
substituted at the nitrogens with a benzoyl group and a phenyl ring. The activity of this structure 
depends on the specific substituents present on the benzoyl and the phenyl rings, and it is 
possible that further elaboration of these domains could lead to higher potency compounds. The 
general structure of AK3 and AK10 does not appear to resemble any present mitotic inhibitor, 
suggesting that they are a new type of mitotic arresting agent. Although these compounds arrest 
mitosis at some point after survivin phosphorylation (at the Cdk1-cyclin B target site), the 
precise nature of this inhibition is not yet known. In vitro tubulin polymerization assays indicate 
that they do not directly target tubulin (data not shown). Whether these agents or their targets 
might be useful for the development of new pharmacological agents is not clear. However, 
understanding their mechanism of action may provide new insight into colon cancer etiology and 
suggest novel approaches to colon cancer treatment and prevention. 
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CHAPTER 3 
Novel piperazine-based compounds inhibit microtubule dynamics and sensitize colon 
cancer cells to TNF-induced apoptosis 
 
3.1. Abstract 
We recently identified a series of mitotically acting piperazine-based compounds that 
potently increase the sensitivity of colon cancer cells to apoptotic ligands. Here we describe a 
structure-activity relationship study on this compound class and identify a highly active 
derivative 1-(3-chlorophenyl)-4-(2-ethoxybenzoyl)piperazine, referred to as AK301, the activity 
of which is governed by the positioning of functional groups on the phenyl and benzoyl rings. 
AK301 induced mitotic arrest in HT29 human colon cancer cells with an ED50 of ≈ 115 nM. 
Although AK301 inhibited growth of normal lung fibroblast cells, mitotic arrest was more 
pronounced in the colon cancer cells (50% vs. 10%). Cells arrested by AK301 showed the 
formation of multiple microtubule organizing centers with aurora kinase A and γ-tubulin. 
Employing in vitro and in vivo assays, tubulin polymerization was found to be slowed (but not 
abolished) by AK301. In silico molecular docking suggests that AK301 binds to the colchicine-
binding domain on β-tubulin, but in a novel orientation. Cells arrested by AK301 expressed 
elevated levels of TNFR1 on their surface and more readily activated caspases-8, -9, and -3 in 
the presence of TNF. Relative to other microtubule destabilizers, AK301 was the most active 
TNF sensitizing agent, and also stimulated Fas- and TRAIL-induced apoptosis. In summary, we 
report a new class of mitosis-targeting agents that effectively sensitizes cancer cells to apoptotic 
ligands. These compounds should help illuminate the role of microtubules in regulating apoptotic 
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ligand sensitivity and may ultimately be useful for developing agents that augment the anti-
cancer activities of the immune response. 
 
3.2. Introduction 
Eukaryotic cell division involves replication of DNA in S phase followed by equal 
segregation of mitotic chromosomes during anaphase [129]. Cell cycle checkpoints have evolved 
to ensure faithful DNA replication and chromosomal division. Cells that harbor defective cell 
cycle checkpoint regulators can result in genetic instability and aneuploidy, ultimately leading to 
tumor development [130]. Mitosis orchestrates multiple cellular changes and depends on many 
intricate signaling pathways, despite being the shortest phase of cell cycle [131]. Signaling 
pathways, including kinases and several checkpoint proteins, spacio-temporally regulate 
dynamic chromosomal rearrangements and reorganization. It is because of this intricacy that 
mitosis is considered the most sensitive phase of the cell cycle [132, 133]. Damage to cellular 
processes that affect mitosis can activate spindle assembly checkpoint (SAC), which delays 
progression into anaphase [134]. Prolonged arrest in mitosis makes the cells more sensitive to 
cellular insults, which has likely made mitosis a desirable target for chemotherapy [132, 135-
137]. Aneuploidies and other genomic and chromosomal abnormalities can induce cellular stress 
on cancer cells and make them highly sensitive to agents that disrupt mitosis [138]. 
Microtubules form spindle fibers during mitosis that are critical for chromosomal 
alignment and segregation [139, 140]. Previous findings suggest that agents that target the 
mitotic spindle can make highly effective chemotherapeutic drugs. Successful use of several 
vinca alkaloids, taxanes, and other natural compounds for the treatment of human cancers has 
validated the effectiveness of microtubule-targeting drugs [141-143]. Several other mitotic 
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proteins have also emerged as potential targets of chemotherapy. These targets include kinases, 
motor proteins, proteasome inhibitors and inhibitors of chromatin reorganizing proteins. Some of 
these newly developed compounds may provide clinical benefits over some of the presently used 
drugs [132]. 
One of the primary challenges of cancer chemotherapeutics is the targeting of cancer 
cells, while sparing normal cells of the surrounding tissue [144]. The use of vaccines and 
immune stimulants to specifically target tumors has generated promising results. For colon 
cancer, complementing traditional chemotherapy with IL2 and GM-CSF was shown to 
significantly increase patient survival [77]. However, immune stimulants can sometimes result in 
modest cell killing activity. Cell killing by the activated immune response includes direct cell 
killing by cytotoxic T cells and NK cells, as well as cell killing apoptotic ligands, such as TNF. 
We previously reported several novel synthetic small molecules that dramatically 
increase colon cancer cell death by TNF and other death ligands, while being unable to induce 
apoptosis on their own [145]. Interestingly, many of these compounds also induced mitotic 
arrest. To gain insight into the mechanisms of action of these compounds, we studied the 
structure-activity relationship of a particularly promising class of piperazine-based compounds. 
Here we report a structure-activity relationship study of this class of compounds and identify a 
highly active derivative, AK301. Furthermore, we show that AK301 hampers tubulin 
polymerization, triggers the formation of multiple microtubule organizing centers (MTOCs), and 
increases the surface expression of TNFR1. Molecular docking studies indicate that AK301 
binds to β-tubulin near the colchicine-binding site, but in a novel orientation. Lastly, AK301 was 
found to be more effective in sensitizing cancer cells to TNF-induced apoptosis than other 
known microtubule destabilizing agents. We propose that AK301 and its derivatives represent a 
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novel class of microtubule-targeting compounds that will be useful for studying the relationship 
between microtubule dynamics and apoptosis sensitivity. This class of compounds may also have 
beneficial therapeutic properties due to their ability to sensitize cancer cells to ligand-induced 
apoptosis. 
 
3.3. Materials and Methods 
3.3.1. Cell culture 
HT29 and HCT116 colon cancer and WI38 fibroblast cell lines were obtained from the 
American Type Culture Collection (Manassas, VA). HT29 and WI38 cell lines were cultured in 
McCoy’s 5A medium and MEM medium, respectively, with 10% fetal bovine serum, non-
essential amino acids and antibiotic/antimycotic (Life Technologies, Guilford, CT). The 
compounds tested were obtained from the ChemBridge DIVERSetTM library (San Diego, CA). 
Drug treatments were performed approximately 24 h after passage for 18 h, unless otherwise 
indicated. TNF was obtained from Pierce Protein Research Products (Rockford, IL), TRAIL was 
obtained from R&D Systems (Minneapolis, MN), and α-Fas antibody (clone CH11) was 
obtained from Millipore (Billerica, MA). 
 
3.3.2. Flow cytometry 
HT29 and WI38 were analyzed for DNA content by ethanol fixation and staining with 
propidium iodide as previously described [89]. Floating and adherent cells were combined and 
analyzed by flow cytometry. Adherent cells were harvested using trypsin-EDTA, centrifuged 
together with the floating cells at 100 X g for 5 min and resuspended in 1 ml of cold saline GM. 
Cells were then fixed by adding 3 ml of cold 100% ethanol while gently vortexing and stored at -
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20°C for at least 2 h. Cells were then pelleted and washed once with PBS containing 5 mM 
EDTA. Pelleted cells were stained with 30 μg/ml propidium iodide (Molecular Probes, Life 
Technologies Corp.) and 0.3 mg/ml RNase A (Sigma-Aldrich, St. Louis, MO) in 1 ml PBS 
solution for 40 min in dark at RT. The stained cells were filtered through 35 μm cell strainer 
tubes (BD Biosciences, San Jose, CA) prior to analysis on FACSCalibur flow cytometry (BD 
Biosciences) using Cell Quest software (BD Biosciences). The data were analyzed using FlowJo 
(version 9.6.2 for Mac, TreeStar Inc., Ashland, OR). 
 
3.3.3. Cell viability assay 
Cell viability was assessed using Trypan blue exclusion assay. After treatment, the cells 
were incubated with Trypan blue at room temperature. Viable/dye excluding cells were then 
counted using a hemocytometer. 
 
3.3.4. Immunofluorescence microscopy 
Cells cultured on coverslips were fixed with 4% paraformaldehyde or 100% ice cold 
methanol and then permeabilized with 0.5% Triton X-100 in PBS. Cells were blocked in 5% 
serum (in PBS) and then incubated for 1 h at room temperature on the shaker with the primary 
antibody (in 5% serum) against phosphohistone H3 Ser 28 (sc-12927, Santa Cruz Biotechnology, 
Santa Cruz, CA), β-tubulin (E7 monoclonal antibody, Developmental Studies Hybridoma Bank), 
or aurora kinase A (BD Biosciences). γ-tubulin antibody (Abcam, Cambridge, MA) incubation 
was performed overnight at 4°C. Appropriate secondary antibodies (Jackson ImmunoResearch, 
West Grove, PA) were used for 45 min incubation. Nuclei were visualized using DAPI (5 μg/ml 
in PBS; DI306, Life Technologies). Coverslips were mounted on slides using ProLong Gold 
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Antifade Reagent (Life Technologies). Images were acquired using Nikon A1R Confocal 
Microscope (version 2.11, Nikon Instruments Inc.) and NIS-Elements Advanced Research 
Software (version 4.13.01, build 916, Nikon Instruments Inc.). Quantification of immunostaining 
was performed using ImageJ image analysis software (http://rsb.info.nih.gov/ij) as previously 
described [88]. Following background subtraction and image stacking, both DAPI and 
immunofluorescence images were merged. Image brightness and contrast was modified with 
Adobe Photoshop software CS6 (Adobe Systems). 
 
3.3.5. In vitro tubulin polymerization assay 
The HTS-tubulin polymerization assay kit (BK004P, Cytoskeleton, Inc, Denver, CO) was 
used as per manufacturer instructions. The reaction assay contained 100 μl of 4 mg/ml tubulin in 
G-PEM buffer (80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM MgCl2, and 1 mM GTP. 10 μl of 
10X compounds were pre-warmed to 37°C in a half area 96-well plate (dH2O was used as 
control). The polymerization was carried out at 37°C and light scattering was recorded at 340 nm 
every minute for 60 min using Spectramax M2 absorbance plate reader (Molecular Devices, 
Sunnyvale, CA). 
 
3.3.6. Whole cell microtubule analysis 
Microtubules in whole cells were analyzed by flow cytometry as described previously 
[146]. Cells were cultured in 24-well plates for 24-36 hrs and treated with the colchicine, 
AK301, or AK302 for 16 hrs. The medium was collected and the cells were harvested by trypsin 
EDTA treatment and pelleted by centrifugation at 600 x g for 5 min. Cell pellets were 
resuspended and fixed with 0.5% glutaraldehyde under permeabilizing conditions in microtubule 
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stabilizing buffer (MTSB; 80 mM PIPES (pH 6.8), 1 mM MgCl2, 5 mM EDTA, and 0.5% Triton 
X-100) for 10 min. Glutaraldehyde was quenched with 700 μl of 1 mg/ml NaBH4 in PBS. Cells 
were pelleted by centrifugation at 1000 x g for 7 min. Cells were blocked with 5% donkey serum 
and immunostained with β-tubulin (E7 monoclonal) antibody for 1 hr at RT, followed by 
secondary staining with Alexa Fluor® 488 donkey anti-mouse antibody (Life Technologies) for 1 
hr. Finally, cells were pelleted by centrifugation and treated with 0.3 mg/ml of RNase A and 50 
μg/ml of propidium iodide solution in PBS. Cells were analyzed by flow cytometry. All steps in 
this protocol were carried out at room temperature. 
 
3.3.7. In silico molecular docking 
Structural representations of the ligand molecules (AK3, AK301, AK302, AK303, and 
AK304) were drawn using Accelrys Draw (version 4.1, Accelrys, Inc.) in MOL2 format and 
converted to PDB format using Accelrys Discovery Studio Client (version 3.5). Individual PDB 
files were modified in AutoDock using MGLTools 1.5.6 (Scripps Institute, La Jolla, CA). 
Crystal structures of tubulin complexed with colchicine, paclitaxel, and vinblastine (PDB IDs 
1SA0 [147], 1TUB [148], and 4EB6 [149], respectively) were obtained from the Protein Data 
Bank. Water molecules, ligands and other heteroatoms were removed from the protein molecules 
using Accelrys Discovery studio client (version 3.5, Accelrys, Inc.). Addition of hydrogen atoms 
to the protein was performed using MGLTools (version 1.5.6) for AutoDock. For each known 
ligand type, grid maps were generated that corresponded to their respective known binding sites 
on tubulin. 
AutoDock 4.2 and Vina 1.1.2 were used for initial docking studies [150]. Generally, the 
docking parameters were left to the default settings. However, the grid spacing was changed 
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from 0.375 to 1.0. The size of the grid was 30 Å X 30 Å X 30 Å. The internal scoring function 
was used to assess receptorligand interactions in five independent runs. 
Additionally, Molegro Virtual Docker (MVD) software version 6.0 was used to perform 
computer simulated docking analysis in order to confirm the least-energy poses acquired using 
AutoDock Vina. Charges for both tubulin and the ligands were calculated by MVD and assigned 
to their respective models. Moreover, probable explicit hydrogens were added to tubulin as well 
as the ligands, possible missing bonds were assigned, and side chain minimization was 
performed. Finally, flexible torsions were manually applied to the ligands. Since tubulin is a 
relatively large protein, a molecular surface was created using MVD workspace grid points and 
top three cavities were identified using expanded van der Waals method for the molecular 
surface with volumes ranging from 5 to 10,000 cubic units and default settings. To perform 
docking, the cavity containing the colchicine-binding domain was used with a radius of 20 to 
cover the entire cavity. MolDock score with a grid resolution of 0.30 Å was used as a scoring 
function for the simulation [151]. Ten runs were performed for each of the ligands using 
MolDock simplex evolution (SE) algorithm for fast and accurate docking and scoring. 1500 
iterations were performed for each of the runs to achieve least minimized energy poses for the 
ligands. During the virtual screening process, internal electrostatic interaction and hydrogen 
bond between ligand and protein were permitted. Energy minimization and H-bond optimization 
was applied to each of the poses post run. 
 
3.3.8. Caspase-3 assay 
Caspase-3 activity was determined as previously described [87, 145]. Cells were 
collected, centrifuged at full speed, and washed once with PBS. Pelleted cells were lysed by two 
56 
rounds of freeze-thaw in lysis buffer containing 10 mM Tris-HCl (pH 7.5), 0.1 M NaCl, 1 mM 
EDTA, and 0.01% Triton X-100 and centrifuged at 10,000 X g for 5 min. The assays were 
performed on 96-well plate by mixing 50 μl of lysis supernatant with 50 μl of 2X reaction mix 
(10 mM PIPES pH 7.4, 2 mM EDTA, 0.1% CHAPS, 10 mM DTT) containing 200 nM of the 
fluorogenic substrate Acetyl- Asp-Glu-Val-Asp-7-Amino-4-methylcoumarin (DEVD-AMC; 
Enzo Life Sciences). The fluorescence was quantified at the start of the reaction and after 30 
min. Protein concentrations were determined using CBQCA Protein Quantitation Kit (Life 
Technologies). Caspase activity was determined by dividing the change in fluorescence by total 
protein content of the reaction mixture. 
 
3.3.9. Western blot 
RIPA buffer was used for total protein extraction and NP-40 buffer was used for 
membrane protein extraction [145]. 20 μg of protein was denatured under reducing conditions 
[90, 91] and separated on 4-20% gradient gels (Bio-Rad Hercules, CA) and transferred to 
nitrocellulose by voltage gradient transfer. The resulting blots were blocked with 5% (w/v) non-
fat dry milk in PBS + 0.1% (v/v) Tween-20. Specific proteins were detected with appropriate 
antibodies using Signal- FireTM Elite ECL Reagent (Cell Signaling Technology, Inc., Danvers, 
MA). Immunoblotting antibodies were cleaved caspase-8 (18C8, Cell Signaling Technology), 
caspase-9 (human-specific, Cell Signaling Technology), TNFR1 (H-5, Santa Cruz 
Biotechnology), E-cadherin (G-10, Santa Cruz Biotechnology), and β-actin antibody (I-19, Santa 
Cruz Biotechnology). 
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3.3.10. Cell surface TNFR1 analysis 
Cells were treated in a 24-well plate as described above. Treated live cells were 
transferred to ice, washed once with PBS and blocked with 5% donkey serum. Cells were 
immunostained with TNFR1 antibody overnight at 4°C, followed by staining with Alexa Fluor® 
488 antibody for 1 hr at RT. Cells were fixed with 4% PFA, washed, and harvested by trypsin 
EDTA. Cells were pelleted by centrifugation and analyzed by flow cytometry. 
 
3.3.11. Statistical analyses 
All results are reported in triplicates as mean ± standard error of mean, unless specified 
otherwise. One-way analysis of variance (ANOVA) was used for comparing more than two 
groups. Tukey’s post-hoc test was employed to determine the significance of differences 
between multiple groups, with P < 0.05 considered significant. Two-way ANOVA was used for 
more than two independent variables and Bonferroni correction was used for multiple 
comparisons (P < 0.05). 
 
3.4. Results 
3.4.1. Functional groups of AK3 mediate mitotic arrest in HT29 cells 
In previous studies, we identified AK3 compound from the ChemBridge DIVERSetTM 
library that induced mitotic arrest in colon cancer cells at low micromolar concentrations (0.5-1 
μM) [145]. To assess properties of the chlorophenyl and methoxybenzoyl functional groups of 
AK3, four different AK3 analogs were analyzed for their ability to induce mitotic arrest in HT29 
colon cancer cells at 5 μM (Figure 3.1A). The analogs comprise positional isomers of chloride 
and methoxy groups on the phenyl (AK302) and benzoyl (AK303, AK304) rings, respectively, 
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as well as the substitution of an ethoxy (AK301) for methoxy on the benzoyl ring. Flow 
cytometric analysis of propidium iodide (PI)-stained HT29 colon cancer cells showed that a 
greater percentage of AK3-, AK301-, and AK303-treated cells arrested in G2/M phase of the cell 
cycle compared to untreated, AK302-, or AK304-treated cells (P < 0.0001) (Figure 3.1B). A 
titration of the most active compounds among the analogs (AK3, AK301 and AK303) and an 
assessment of the G2/M arrest by flow cytometry is shown in Figure 3.1C. AK301 induced a 
G2/M arrest more efficiently than AK3 or AK303 with a half maximal effective concentration 
(EC50) value of approximately 115 nM. Further, HT29 cells showed decreased growth in the 
presence of AK3 or AK301, with dose response curves showing a higher potency of AK301 
(Figure 3.1D). Together, these results indicate that the position of the functional groups on AK3 
derivatives play an important role in determining their activity in inducing cell cycle arrest. 
 
3.4.2. AK301 induces ad irreversible mitotic arrest in HT29 cells 
To determine whether AK301-treated cells arrested in mitosis, HT29 cells were analyzed 
for presence of the mitosis marker phospho-histone H3 Ser 28 (p-HH3). Figure 3.2A and 3.2B 
show that both AK3 and AK301 increased phospho-histone H3 Ser 28 staining, consistent with 
mitotic arrest. 
To further assess whether this state of mitotic arrest was reversible, AK301 was washed 
out of the growth medium after 18 hours of treatment and cell growth was observed at 24, 48, 
and 72 hours following drug washout. As shown in Figure 3.2B, AK301-treated cells did not 
recuperate after 72 hours post drug washout and showed significantly less growth compared to 
the untreated cells (P < 0.0001). 
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Figure 3.1. Structural changes in the side groups of AK3 dictate its potency in inducing 
mitotic arrest. 
(A) Structural analogs of AK3 [1-(3-chlorophenyl)-4-(2-methoxybenzoyl)piperazine] with 
modifications to the benzoyl group: AK301 [1-(3-chlorophenyl)-4-(2-ethoxybenzoyl)piperazine], 
AK303 [1-(3-chlorophenyl)-4-(3-methoxybenzoyl)piperazine], and AK304 [1-(3-chlorophenyl)-
4-(4-methoxybenzoyl)piperazine], and the phenyl group [1-(4-chlorophenyl)-4-(2-
methoxybenzoyl)piperazine]. (B) HT29 cells were treated with 5 µM of AK3 analogs for 18 h 
followed by an assessment of G2/M arrest by flow cytometry. Data suggest that AK3, AK301, 
and AK303 induce G2/M phase arrest, whereas AK302 and AK304 are inactive at this 
concentration (*P < 0.0001). (C) Dose-response analysis of AK3, AK301, and AK303-induced 
mitotic arrest by flow cytometry. AK3, AK301, and AK303 were titrated at different 
concentrations between 0 and 500 nM and G2/M was quantified by flow cytometry. AK303 
induced significantly less mitotic arrest compared to AK3- or AK301-treated cells. AK301 was 
found to be the most potent compounds. (D) Dose-response curves showing reduced cell growth 
of AK3- and AK301-treated cells with increasing concentration. Cell viability of AK3- and 
AK301-treated cells were assessed by trypan blue exclusion assay. 
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Figure 3.2. AK301 induces an irreversible mitotic arrest. 
(A) AK3 and AK301 induce mitotic arrest in HT29 cells. Cells treated with 5 µM of AK3 or 
AK301 for 18 h were fixed, permeabilized, and stained with phospho-histone H3 (p-HH3) as a 
marker of chromosome condensation and mitosis. (B) Quantification of p-HH3 staining in Figure 
3.2A shows a greater number of cells in mitosis. (C) Cells were treated with 500 nM of AK301 
for 18 h. AK301 was then wash out and cell growth was observed at 24, 48, and 72 hours. 
AK301-treated cells showed no significant growth after AK301 withdrawal (*P < 0.0001). 
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3.4.3. AK301 affects microtubule function and results in multiple microtubule organizing 
centers (MTOCs) 
To determine the effect of AK301 on spindle formation in the arrested cells, we 
performed immunostaining for β-tubulin. As shown in Figure 3.3A, AK301 induced the 
formation of multiple MTOCs, as is the case for AK3-treated HT29 cells. To further determine if 
the MTOC assemblies were stable or resulted from spontaneous microtubule assembly, HT29 
cells were stained for aurora kinase A (AukA) and γ-tubulin. Aurora kinase A is responsible for 
recruitment of γ-tubulin to established centrosomes and γ-tubulin serves to nucleate and orient 
microtubules. As shown in Figure 3.3B, multiple aurora kinase A and γ-tubulin centers were 
observed following AK301 treatment of HT29 cells. These data suggest that AK301 leads to the 
formation of multiple MTOCs, including deposition of aurora kinase A and γ-tubulin at the 
spindle poles. We performed a dose-response analysis of β- tubulin immunostaining to assess the 
effects of AK301 on the formation of multiple MTOCs. As shown in Figure 3.4A, AK301 
significantly induced spindle impairment or multipolarity compared to the inactive AK302 and 
AK304 at concentrations as low as 50 nM. We also quantified the number of aurora A kinase and 
γ-tubulin foci and found that AK301increased the number of these foci as well 
(Figures 3.4B and 3.4C). 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
Figure 3.3. AK3 and AK301 induce the formation of multiple microtubule organizing 
centers (MTOCs). 
HT29 cells treated with AK3 (1 µM) or AK301 (500 nM) were fixed and stained for (A) β-
tubulin to visualize spindle assembly, (B) Aurora kinase A (AukA) (red; top panel) to understand 
the basis of multiple spindle organization, and γ-tubulin (red, bottom panel) to observe spindle 
nucleation. AK3- and AK301-arrested cells have multiple spindle nucleation sites, from which 
spindles arise. 
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Figure 3.4. Quantification of MTOCs in AK301-treated cells. 
(A) Quantification of cells with impaired spindles visualized by β-tubulin staining show multiple 
spindle poles. Quantification of (B) Aurora kinase A foci in HT29 cells, and (C) γ-tubulin foci in 
HT29 cells suggest the formation of multiple MTOCs in AK301-treated cells (*P < 0.0001).  
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3.4.4. AK301 induces G2 arrest in WI38 lung fibroblast cells 
To assess the effects of AK301 on normal cells, we performed a dose response analysis 
for growth inhibition on WI38 lung fibroblast cells. As shown in Figure 3.5A, WI38 cells treated 
with AK3 or AK301 showed decrease in growth, similar to HT29 cells (Figure 1D). Comparison 
of the cell cycle data between AK301-treated HT29 and WI38 cells showed that AK301 induced 
a G2/M arrest in both cell lines (Figure .5B). However, quantification of mitosis using the 
mitosis-specific phospho-histone H3 staining revealed that AK301 induced significantly higher 
mitotic arrest in HT29 cells compared to WI38 cells (Figure 3.5C). Analysis of AK301-treated 
WI38 cells that were arrested in mitosis showed that they lacked multiple MTOCs and instead 
showed a more extensive microtubule breakdown (Figure 3.5D; arrowheads). AK301 altered 
microtubules of interphase cells; untreated WI38 cells showed elongated and spindle-shaped 
microtubules, whereas AK301-treated cells displayed a mesh-like network of microtubules. 
Together, these results suggest that AK301 can have cell-specific effects and that these effects 
may be mediated by changes in microtubule dynamics. 
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Figure 3.5. AK301 induces G2/M arrest in WI38 lung fibroblast cells. 
(A) Dose-response analysis of WI38 cell growth inhibition by AK3 and AK301. Cells were 
treated with the indicated concentrations of the compounds followed by an assessment of viable 
cell number in the cultures (*P < 0.0001). (B) AK3 and AK301 induce G2/M arrest in HT29 and 
WI38 cells. Comparative cell cycle analysis of G2/M arrest in HT29 and WI38 cells was 
performed by flow cytometry (*P < 0.0001). (C) AK301 induces higher mitotic arrest in HT29 
cells compared to that in WI38 cells. HT29 and WI38 treated with AK301 were immnostained 
for phospho-histone H3 and the mitotic index was determined in at least three microscopic fields. 
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Error bars indicate SEM (*P < 0.0001). (D) AK301-treated WI38 cells showed absence of 
spindle formation in mitotic cells. Treated cells were dual stained for phospho-histone H3 
(green) and β-tubulin (red) to visualize spindle assembly in arrested cells. Arrows indicate 
interphase cells, whereas arrowheads indicate mitotic WI38 cells. AK30 disrupts spindle 
formation as well as cytoskeletal microtubules. 
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Figure 3.6. AK301 reduces the rate of tubulin polymerization. 
(A) and (B) Tubulin subunits were allowed to polymerize in the presence of AK301, AK302, 
paclitaxel, or colchicine for 60 min. Tubulin polymerization (length of microtubules) was 
assayed in terms of absorbance at 340 nm. Assay indicates a decreased rate of tubulin 
polymerization in the presence of AK301, but not with AK302 (inactive compound), compared 
to control.  
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3.4.5. AK301 affects the rate of tubulin polymerization in vitro 
Given the formation of multiple MTOCs in AK301-treated HT29 cells (Figures 3.3A and 
3.3B) and the alteration of microtubule structures in WI38 cells, we assessed the effect of AK301 
on the rate of tubulin polymerization, in an in vitro tubulin polymerization assay. As shown in 
Figure 3.6A, addition of AK301 slowed the rate of tubulin polymerization compared to the 
control sample. In contrast, AK302, identified as the inactive analog of AK3, did not alter the 
rate of polymerization. Colchicine, a known inhibitor of microtubule polymerization, acts by 
binding the β-subunit of tubulin dimer, and prevents their addition to the growing polymer. 
Microtubule formation was almost completely inhibited in the presence of colchicine, compared 
to AK301 (Figure 3.6B). 
To assess the effect of AK301 on microtubule dynamics in vivo, we performed 
quantitative whole cell microtubule analysis as described previously. Figure 3.7A outlines this 
procedure that quantifies the degree of tubulin polymerization by flow cytometry. Figure 3.7B 
shows the mean fluorescence intensity (MFI) of mitotic cells treated with colchicine (500 nM), 
AK301 (250 nM), and its inactive analog, AK302 (1 μM). Colchicine shows the lowest 
microtubule fluorescence intensity, consistent with microtubule destabilization by colchicine. 
However, AK301-treatment shows a staining intensity intermediate to that of control and 
colchicine. AK302 did not induce significant reduction in staining. These data, along with the in 
vitro experiments, suggest that AK301 induces a partial breakdown of microtubules. 
 
3.4.6. In silico molecular modeling 
We performed molecular docking studies to assess tubulin as the potential target of AK301. We 
employed automated docking using AutoDock Vina with tubulin as the target receptor and 
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assessed SAR of the analogs to identify in silico conformations [150]. Colchicine, paclitaxel, and 
vinblastine were docked to their respective sites on tubulin to check for accuracy of molecular 
docking predictions (Figure A3; Figures A4A and A4B) [147-149]. AK3 and its analogs were 
docked to β-tubulin in the colchicine-, paclitaxel-, and vinblastine-binding sites. AutoDock Vina 
reported multiple conformations and corresponding binding affinities for each of the compounds 
in five independent trials. AK3 and its active analogs, AK301 and AK303, docked in same 
positions as indicated by superimposition of central piperazine core and the flanking functional 
groups of the small molecules (Figure A4C). The lowest energies for different compounds in 
known binding sites are shown in Table 1.1. Control binding affinities correspond to the energies 
obtained by docking colchicine, paclitaxel, vinblastine, and vincristine into their respective 
binding sites (vinblastine and vincristine were docked into the high affinity sites on tubulin). 
Active AK3 analogs showed compatibility for the colchicine site. In addition, the order of the 
predicted binding affinity matched the potency of AK3 analogs, as predicted by SAR studies. 
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Figure 3.7. Disruption of in vivo microtubules in HT29 colon cancer cells. 
(A) Schematic description of the methodology used for the assessment of in vivo microtubule 
stability in HT29 cells after AK301 treatment. (B) HT29 cells were treated with 500 nM 
colchicine, 250 nM AK301, or 1 µM AK302. Mean fluorescence intensity of mitotic cells was 
determined as described above. Data indicate decreased microtubule stability in AK301 and 
colchicine-treated cells, relative to AK302-treated and control cells (*P < 0.0001).  
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Figure 3.8A shows an in silico model of AK301 binding to tubulin in the colchicine-binding 
domain. Although AK301 docked into the colchicinebinding site, it assumed a different, novel 
orientation relative to colchicine. This orientation allows for hydrogen bond interactions between 
the oxygen atom of the ethoxy group or the carbonyl group and Asn 101 residue (3.0 Å and 2.9 
Å, respectively). Further, this places the hydrophobic chloride proximal to hydrophobic tubulin 
residues—Leu 255 (3.9 Å) and Ile 378 (3.5 Å) (Figure 3.8B). In contrast, moving the chloride 
group from 3’ C to 4’ C of the halophenyl ring to generate the less-active AK302 compound 
changes the conformation of the molecule in the tubulin binding site. The changed conformation 
of AK302 decreased hydrophobic interactions with Leu 255 (6.7 Å) and Ile 378 (9.6 Å), and 
increased the distance for hydrogen bond interactions (6.6 Å for methoxy group and 5.8 Å for the 
carbonyl group) at the other end of the molecule (Figure 3.8C). Similar changes in conformation 
were also observed when the position of the methoxy group was moved from 2’ C to 4’ C, as is 
the case with AK304 compound. In general, the docking scores obtained correlated with the 
predicted in vitro activity and fit the SAR of AK3 analogs, with AK301 being the most potent 
among the analogs (Table 1). To confirm AK301 binding in the colchicine- binding domain of 
tubulin, we also performed molecular docking simulations in Molegro Virtual Docker [151]. We 
performed ten runs for AK301, targeting the largest cavity in tubulin, containing the colchicine-
binding domain of tubulin. MolDock scoring function was used to assess the binding of the 
lowest energy poses. AK301, as predicted by AutoDock Vina, docked to the colchicine-binding 
domain of tubulin with the least energy poses superimposing each other (Figure 3.8D). The 
specific functional groups and their positions may, therefore, play an important role in 
determining the potency of AK3 analogs in inducing mitotic arrest in colon cancer cells. 
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Table 3.1. Predicted binding energies (in kcal/mol) of AK3 analogs docked in colchicine, 
paclitaxel, and high-affinity vinblastine site on β-tubulin. 
 
Compound Colchicine site Paclitaxel site Vinblastine site 
Control -8.8# -9.7† -10.7/-10.0‡ 
AK301 -8.7 -7.3 -7.5 
AK3 -8.2 -7.3 -7.5 
AK303 -8.3 -7.4 -7.6 
AK302 -8.1 -7.3 -7.5 
#colchicine, †paclitaxel, ‡vinblastine/vincristine 
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Figure 3.8. Predicted in silico novel binding orientation of AK301 to β-tubulin. 
(A) Novel orientation of AK301 in the colchicine-binding site of β-tubulin as modeled by 
AutoDock. AK301 (shown in green) is predicted to bind to tubulin the colchicine-binding 
domain (colchicine is shown in red), but in a different orientation. (B) Residues surrounding 
AK301 allow for strong hydrogen bond interactions with Asn101 of β-tubulin. Consequently, the 
chloride group is positioned in tubulin surrounded by hydrophobic residues (Leu255 and Ile378). 
(C) Changing the position of the chloride in AK3 from 3’ C to 4’ C generates the inactive 
compound AK302. This change disrupts the hydrogen bond interactions of the methoxy and 
carbonyl groups on the methoxy-substituted benzoyl ring. Decreased hydrogen bond interactions 
result in lower binding affinity of AK302 to tubulin (Table 3.1). (D) Least energy poses of 
AK301, as predicted by AutoDock Vina (gray) and Molegro Virtual DOcker (green), docked to 
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β-tubulin. The least energy pose of AK302, predicted by MVD, had a similar orientation to that 
predicted by AD Vina.  
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3.4.7. TNF-dependent induction of apoptosis in AK301-treated cells 
AK3 and other piperazinebased compounds were originally identified by their ability to 
acutely sensitize colon cancer cells to ligand-induced apoptosis [145]. To determine whether 
AK301 could also induce cell death in combination with TNF, we performed a dose-response 
analysis of AK301 in the presence and absence of TNF (Figure 3.9A). Analysis of the sub-
diploid cell population indicated that AK301, on its own, did not induce apoptosis in HT29 colon 
cancer cells. However, in the presence of TNF, AK301- treated cells underwent significant 
apoptosis (EC50 of 172 nM) at concentrations approximately 5 times lower than those reported 
for AK3 [145]. 
To determine the association between mitotic arrest and TNF-induced apoptosis, the 
compounds shown in Figure 1A were tested for their ability to induce apoptosis in the presence 
of TNF. Figure 3.9B shows that only the compounds that induced a mitotic arrest could induce 
apoptosis in combination with TNF. This finding suggests an association between mitotic arrest 
and TNF sensitivity. To further assess the correlation between the two events, cell cycle analysis 
of HT29 cells was performed. As shown in Figure 3.9C, most of the cells in the control 
population are in the G1 phase of cell cycle. With TNF treatment alone, no significant shifts are 
observed. However, with the addition of AK301, cells shifted from G1 to G2/M. Finally, co-
treatment of HT29 cells with AK301 and TNF resulted in a decrease in G2/M population and a 
subsequent appearance of sub-diploid population. These data suggest that the sub-diploid 
population is likely derived from the G2/M arrested cells. 
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Figure 3.9. AK301-induced mitotically arrested cells undergo TNF-dependent apoptosis. 
(A) Dose-response analysis of AK301-treated cells in the presence and absence of TNF. HT29 
cells were treated with AK301 (500 nM) or AK301 plus TNF (50 ng/ml) for 18 h, PI-stained and 
analyzed by flow cytometry. Significant apoptosis was observed only in the combination 
treatment (*P < 0.0001). (B) Induction of cell death following combination treatment with active 
AK3 analogs and TNF. Cells were treated with 5 µM of AK3, AK301, or AK303 and TNF (50 
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ng/ml) showed high percentage of sub-diploid population compared to TNF treatment alone (*P 
< 0.0001). Percentages of sub-diploid population with 5 µM of AK302 or AK304 and 50 ng/ml 
of TNF treatment were similar to those treated with TNF alone. (C) AK301 induces mitotic 
arrest and the appearance of sub-diploid cell fragments in the presence of TNF. In the presence 
of AK301 alone (500 nM), cells arrest in G2/M phase of mitosis (bottom, left panel). In the 
presence of TNF alone, there is no significant change in the cell cycle distribution (top, right 
panel). Following combination treatment with Ak301 and TNF (50 ng/ml), a decrease in the 
G2/M population was observed accompanied by the appearance of a sub-diploid population (*P 
< 0.0001).  
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3.4.8. Relationship between mitotic arrest and cancer cell apoptosis 
To further examine the relationship between mitotic arrest induced by AK301 and its 
analogs and apoptosis, we performed a dose-response analysis of AK301, AK302, and AK304 
on mitotic arrest and caspase-3 activation. As shown in Figure 3.10A, AK301 induced mitotic 
arrest in a dose-dependent manner, whereas AK302 and AK304 were inactive even at 
concentrations of 5 μM. Analysis of dose-dependent caspase-3 activity (using DEVD-AMC 
fluorogenic substrate) for these compounds in the presence of TNF is shown in Figure 3.10B. 
Data indicates similar trends in caspase-3 activation as those observed for mitotic arrest. These 
results demonstrate a close relationship between mitotic arrest by AK301 and TNF-induced 
apoptosis. 
There are a number of known inhibitors of microtubules that are capable of inducing 
mitotic arrest [152-154]. To determine how these compounds compare to AK301 in sensitizing 
cells to TNF, HT29 cells were treated with two different concentrations each of AK301, 
colchicine, nocodazole, and a vinca alkaloid—vincristine in the absence or presence of TNF for 
18 hours. Cell extracts were prepared for capase-3 enzymatic assay. As shown in Figure 3.10C, 
none of the compounds induced caspase-3 activation on their own. However, upon co-treatment 
of HT29 cells with the drugs and TNF, significant caspase-3 activation was observed (Figure 
3.10D). Interestingly, AK301 induced the highest levels of caspase-3, even at 125 nM (P < 
0.0001). Together with the results of previous experiments, this suggests that AK301 is a novel, 
potent inhibitor of microtubules capable of inducing arrest on its own and increasing cell 
sensitivity to TNF-induced apoptosis. 
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Figure 3.10. Effect of microtubule disruption on colon cancer cell apoptosis in the presence 
of TNF. 
(A) Dose-response analysis of AK301, AK302, and AK302 mitotic arrest of HT29 cells. Cells 
were stained with p-HH3 post treatment and the mitotic index was determined. Data indicate a 
dose-response mitotic index in cells treated with AK302. (B) Dose-response analysis of AK301, 
AK302, and AK304 caspase activation in HT29 cells. Cell lysates were prepared and tested for 
caspase-3 activity using DEVD-AMC fluorogenic substrate. Data indicate dose-response of 
caspase-3 activation in cells treated with AK301, similar to mitotic index in Figure 3.10A (#P < 
0.05, ‡P < 0.01, *P < 0.0001). HT29 cells were treated with microtubule inhibitors in the absence 
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(C) or presence (D) of TNF (50 ng/ml). AK301 and other known microtubule inhibitors 
(colchicine, nocodazole, and vincristine) did not induce significant levels of caspase-3 activity on 
their own (panel A). However, in combination with TNF, AK301 induced significantly higher 
levels of caspase-3 in HT29 cells, relative to the other microtubule destabilizers (panel B) (*P < 
0.0001). 
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3.4.9. Generality of AK301 activity 
To assess the general effects of AK301 sensitization, we determined the effect of AK301 
on caspase-3 activation by TRAIL and Fas. As show in Figure 3.11A, AK301 enhanced TRAIL-
induced caspase-3 activity. HT29 cells were more sensitive to Fas ligation, but AK301 further 
enhanced Fas-induced caspase-3 activity, as shown in Figure 3.11B. AK301 was also tested on 
HCT116 cells, another human colon cancer cell line (Figure 3.11C). HCT116 cells were more 
sensitive to TNF-induced apoptosis than HT29 cells. Despite their sensitivity, AK301 
significantly enhanced TNF-induced caspase-3 activation over TNF background. (#P < 0.01). 
These data suggest that AK301 is broadly active on different cancer cell lines and with different 
death ligands, such as TRAIL and Fas. 
 
3.4.10. Increased TNFR1 cell surface expression mediates enhanced caspase-8 and caspase-9 
activation 
TNF is coupled to caspase-8 through TNFR1, which in turn can activate procaspase-3 
[155]. Moreover, activated caspase-8 can interact with the intrinsic death pathway by activating 
caspase-9 [156]. We analyzed the presence of caspase-8 and -9 in AK301 and AK301/TNF 
treated cells by immunoblotting. As shown in Figure 3.12A, AK301 or TNF treatment alone did 
not induce caspase-8 or caspase-9 activation. However, cells co-treated with AK301 and of both 
of these caspases. 
To determine if caspase-8 was activated by an increased TNF-TNFR1 coupling at the cell 
surface, we assessed the levels of TNFR1 in the membrane fraction of HT29 cells (an NP40 
extract) relative to a whole cell extract (RIPA). As shown in Figure 3.12B, cells treated with 
AK301 showed an increase in the appearance of TNFR1 in the membrane fraction. Moreover, 
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we observed an increase in TNFR1 in the RIPA extract after treatment with AK301 or TNF 
alone, which suggests that AK301 may act as a trigger for TNFR1 production. We quantitatively 
analyzed cell surface expression of TNFR1 in HT29 cells after treatment with AK301 analogs to 
determine if TNFR1 surface expression was specific to AK301. As shown in Figure 3.12C, 
HT29 cells treated with AK301 showed an increase in TNFR1 cell surface staining, whereas the 
other inactive analogs did not. Together, these data suggest that AK301 induces an increase in 
cell surface expression of TNFR1. This increase in surface expression may facilitate TNF 
binding and trigger an apoptotic cascade. 
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Figure 3.11. Effect of AK301 on other colon cancer cell lines and on TRAIL- and Fas-
mediated cell death. 
AK301 accentuated caspase-3 activation in the presence of (A) TRAIL, or (B) by Fas ligation. 
AK301-treated HT20 cells were co-treated with TRAIL (20 or 40 ng/ml) or anti-Fas antibody 
(10 µg/ml) and analyzed for caspase-3 activation. Both TRAIL and Fas ligation significantly 
enhanced caspae-3 activation, despite HT29 cells being more sensitive to Fas ligation (*P < 
0.0001). (C) TNF was titrated on to HCT116 colon cancer cells in the presence or absence of 500 
nM of AK301. AK301 significantly increased caspae-3 activity as observed by DEVD-AMC 
cleavage (*P < 0.0001), even though HCT116 cells are inherently more sensitive to TNF-
induced cell death. 
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Figure 3.12. Increased TNFR1 cell surface expression and caspase-8 activation in AK301-
treated cells. 
(A) AK301 enhances TNF-induced activation of caspase-8 and caspase-9 (*P < 0.0001). Cells 
treated with AK301 for 16-18 h in the presence or absence of TNF. Immunoblot analysis of cell 
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lysates with antibodies against fill length and cleaved caspase-8 and caspase-9 showed cleaved 
caspase-8 and caspase-9 in cells co-treated with AK301 and TNF. (B) AK301 induces increased 
cell surface expression of TNFR1 on HT29 cells. Immunoblot analysis of an NP40 fraction 
(membrane proteins) and RIPA fraction (total protein/cell lysate) showed an increase in TNFR1 
in the membrane fraction post AK301 treatment. (C) Increase in cell surface TNFR1 expression 
by flow cytometry. HT29 cells were treated with AK301 and its less active analogs were stained 
for TNFR1 and then fixed for flow cytometry. Data indicate increased cell surface expression of 
TNFR1 in AK301-treated cells, but not with the inactive analogs of AK301. 
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3.5. Discussion 
We previously identified a class of small molecules that induced mitotic arrest in colon 
cancer cells and sensitized these cells to apoptosis in the presence of death ligands, such as TNF 
and FasL [145]. Here, we performed a detailed structure-activity relationship study on a 
piperazine-based compound (AK3) that was initially found to be highly effective at sensitizing 
colon cancer cells to apoptosis. Specifically, we identified 1-(3-chlorophenyl)-4-(2-
ethoxybenzoyl)piperazine, referred to as AK301, that can induce mitotic arrest in colon cancer 
cells with an EC50 of ≈ 115 nM. This derivative is approximately five-fold more potent than the 
original AK3 compound identified in the initial screen. AK301 also increased the sensitivity of 
HT29 and HCT116 human colon cancer cell lines to TNF-induced apoptosis at relatively low 
concentrations. AK301 was also capable of inducing cell death in the presence of TRAIL and 
FasL. Our SAR studies also revealed a number of related compounds that were inactive for both 
mitotic arrest and TNF sensitization (AK302 and AK304). Together these compounds indicate a 
close relationship between mitotic arrest and sensitivity to TNF-induced apoptosis. In addition, 
these molecules were employed to determine a potential cellular target leading to mitotic arrest 
and apoptosis. 
Characterization of the mitotic arrest state of AK301-treated cells indicated multipolar 
spindle assembly. The formation of the multipolar spindles was accompanied by appearance of 
multiple γ-tubulin and aurora kinase A staining loci, which is consistent with disruption of 
centrosome regulation and bipolar spindle formation. Most cancer cells have over-replicated 
centrosomes [157, 158], which are clustered at the poles during mitosis [159]; disruption of 
centrosome clustering by disruption of microtubule spindles by AK301 may prevent the 
concerted segregation of supernumerary centrosomes and lead to spindle multipolarity [160]. 
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These complex, multipolar structures are apparently difficult to resolve as cell division is 
significantly inhibited even after the removal of AK301. The degree of AK301-induced mitotic 
arrest is cell-type dependent. Proliferation of the WI38 lung fibroblast cell line was reduced by 
AK301, but cells arrested more frequently in G2 than in mitotic phase. Although the reason for 
this difference in arrest phase is not known, it may be related to the presence of functional cell 
cycle checkpoints in non-transformed WI38 cells. Previous studies have shown that the 
checkpoint with forkhead and ring finger domains (CHFR) protein is a critical component in the 
cellular response to mitotic stress (including stress induced by microtubule disruption [161, 162]. 
Cells expressing a functional CHFR protein can delay entry into mitosis, thereby preventing 
catastrophic events during mitosis [163, 164]. On the other hand, studies have shown that HT29 
cells and other cancer cells down-regulate CHFR expression (through promoter hyper-
methylation) and are more likely to enter mitosis and not recover [165, 166]. The lack of 
functional mitotic checkpoints likely contributes to the effectiveness of mitosis-targeting 
chemotherapeutic agents and may explain to the different responses of HT29 and WI38 cells to 
AK301. However, microtubule disruption was observed in both arrested HT29 cells and WI38 
interphase cells treated with AK301. This finding suggests that AK301 may target microtubules. 
This target is further supported by in vitro and in vivo tubulin polymerization studies and by in 
silico docking of AK301 to tubulin. It remains possible that AK301 interacts with other cellular 
proteins to achieve its effect of the cell cycle arrest and apoptosis, but all our dose-response and 
structure-activity studies point to microtubules as being an important target. 
Microtubules are filamentous polymers of the cytoskeleton, composed of repeating α/β 
tubulin heterodimers, responsible for determining cell shape, motility, intracellular transport, and 
cell division [131]. Microtubules have long been known as the drivers of chromosome migration 
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and chromosome segregation [167]. Microtubules become highly dynamic during mitosis and 
generate bipolar spindles that capture the sister chromatids and align them at the equatorial plate 
[168, 169]. With proper chromosome alignment and cellular signaling, cells enter into anaphase 
and complete cell division [170]. The importance of microtubules in mitosis has made them a 
fruitful target for cancer therapies. However, it is clear that not all tubulin disruptors are equally 
useful as cancer therapies. This may be due in part to their influence on apoptosis pathways. 
Here we show that among microtubule disruptors, AK301 is particularly potent at sensitizing 
cancer cells to TNF and other apoptotic ligands. The interaction of microtubules with apoptosis 
is not limited to disrupting agents since paclitaxel can also sensitize cancer cells to TNF [171]. 
The mechanism by which apoptotic signaling is enhanced by microtubule targeting agents is not 
clear, but further study of this effect could improve our understanding of apoptosis regulation 
and may lead to the generation of more effective microtubule targeting agents. Our present data 
point to an increase in the expression of TNFR1 on the surface of cancer cells. 
Molecular docking was employed to assess the potential of AK301 binding to tubulin 
dimers. For this analysis, we focused on the microtubule binding sites for colchicine, paclitaxel, 
and vinblastine. Molecular docking defines energy-optimized ligand orientations formed 
between the drug and its receptors [172]. Molecular docking predictions of AK301 and its 
derivatives showed relatively high affinity for the colchicine-binding region of tubulin, but 
docked in a different orientation than colchicine. Further analysis of these in silico complexes 
supported the significance of this binding position; we found that the longer chain ethoxy group 
of AK301 favored strong hydrogen bond interactions and positioned the chlorophenyl ring in a 
hydrophobic pocket. In summary, this theoretical structural analysis predicted the affinity of 
AK301 for tubulin. 
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We propose that AK301 represents a novel class of mitotic inhibitors, capable of 
inducing mitotic arrest on its own and inducing apoptosis in combination with TNF with high 
efficiency. How mitotic arrest leads to ligand-dependent cell death is not fully understood. We 
previously showed that mitotically arrested cells have increased cell surface expression of 
TNFR1 [145]. Increased TNF-TNFR1 interactions at the cell surface (or following TNF 
internalization) may increase the formation of death-inducing signaling complex (DISC) and 
caspase-8 activation [173, 174], which has been observed in arrested cells. Interestingly, AK301 
was the most potent TNF-sensitizing agent tested in these studies, relative to other well-studied 
microtubule inhibitors (colchicine, nocodazole, and vincristine). How AK301 achieves such a 
high degree of TNF sensitization is not clear. Based on our tubulin polymerization assay, AK301 
reduces the rate of tubulin polymerization, but does not prevent it completely (like colchicine). 
We speculate that AK301 interferes with tubulin polymerization, but just enough such that the 
cells can continue to deliver and present TNFR1 and/or Fas on the cell surface. However, it 
should be noted that AK301 might possibly interact with a microtubule-related target or an 
upstream target that affects tubulin polymerization. The activity of the AK301 class of 
compounds, both as effective mitotic inhibitors and as apoptotic ligand-sensitizing agents, 
suggests that they may be well-suited for cancer treatment, particularly when used on cancers 
with a high inflammatory cell infiltrate or following treatment with an immune stimulant. For 
basic research applications, this class of compounds should help illuminate how microtubules are 
employed to regulate apoptosis sensitivity. 
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CHAPTER 4 
Novel microtubule inhibitor AK301 promotes the mitosis-to-apoptosis transition 
 
4.1. Abstract 
Precise genomic division during mitosis is a well-orchestrated process, mediated by 
microtubule spindles. Mistakes in the genomic division may result in cell cycle arrest or 
apoptosis, and if unchecked, can drive chromosome instability and tumorigenesis. Mitotic 
inhibitors are widely utilized chemotherapeutic agents, which take advantage of the high 
proliferative nature of cancer cells and defects in their m itotic checkpoints. We have identified a 
class of novel piperazine-based microtubule inhibitors, of which AK301 (1-(3-chlorophenyl)-4-
(2-ethoxybenzoyl)piperazine), is the most potent derivative identified to date. Compared to other 
mitotic inhibitors, we show that AK301-arrested cells readily enter apoptosis following 
compound withdrawal or death ligand treatment (IC50 ≈ 150 nM). This effect was more 
pronounced in p53-normal colon cancer cells. AK301-treated cells also exhibited higher levels of 
mitosis-associated ATM signaling and caspase-3 activation. Immunofluorescence confocal 
imaging of AK301-treated cells revealed the formation of characteristic multiple microtubule 
organizing centers and reduced microtubule growth. Upon AK301 withdrawal, microtubule 
networks and spindles reformed and readily entered apoptosis. In summary, our data show the 
development of a new class of mitotic targeting agents that may be useful for further drug 
development. This class of compounds can also serve as chemical probes for studying 
microtubule dynamics and cell signaling pathways regulating the mitosis-to-apoptosis transition. 
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4.2. Introduction 
Mitosis is an intricate process in actively dividing cells, orchestrating a myriad of kinases 
and signaling pathways [129, 175]. Ascribing to this complexity, mitosis is considered to be the 
most sensitive phase of the cell cycle [132]. A number of mitotic checkpoints ensure the fidelity 
of chromosome segregation and cytokinesis; failure of mitotic checkpoints often results in 
chromosomal alterations, culminating in mitotic catastrophe or cancer-promoting chromosomal 
instability [130, 133]. Cancer cells often lack important checkpoint activities and will execute 
mitosis with improper spindle assembly [130]. Therefore, mitotic inhibitors are among the most 
widely utilized chemotherapeutic agents in the treatment of a number of malignancies [132]. 
However, the response of the cancer cells to mitotic inhibitors can be distinctly different–some 
cells remain arrested in mitotic phase, while others exit division and undergo apoptosis [176, 
177]. In addition, different mitotic inhibitors result in varying levels of apoptosis [132]. How 
microtubule disrupting agents result in apoptosis and what cellular factors make the decision of 
mitotic arrest to apoptosis remain elusive. Previous studies indicate that the spindle assembly 
checkpoint (SAC) during mitosis is necessary for efficient induction of apoptosis; compromising 
SAC significantly reduces the sensitivity of anti-mitotic agents, including microtubule poisons 
[178, 179]. Thus, it is important to understand alterations in mitotic processes to effectively 
target cancer cells for apoptosis. 
The SAC is enforced by a complex of proteins, including MAD2, BUB1, BUBR1, 
CHFR, and several others that are recruited to the kinetochores and centrosomes to ensure proper 
segregation of genetic material. MAD2, BUB1, and BUBR1 form the core of the SAC, while 
proteins, such as CHFR, act as modulators of spindle checkpoint by coordinating early mitotic 
progression and delaying chromosome condensation in cases of mitotic stress [180, 181]. 
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Prolonged mitotic arrest due to activation of the SAC may result in senescence or apoptosis [177, 
182]. Inactivation of checkpoint in cancer generally occurs through mutations in the core SAC 
proteins, suppressing the activity of mitotic checkpoint. In addition, studies also evidence 
inactivation of CHFR gene through hypermethylation [181]. Cancer cells, therefore, usually 
exhibit a dysfunctional mitotic checkpoint to continue to divide without restrictions imposed by 
the SAC. 
One of the major hallmarks of cancers is the suppression of apoptotic responses [22]. The 
p53 protein is a tumor suppressor that acts as a guard against a variety of stress signals and 
mediates cellular arrest and/or apoptosis [183, 184]. Studies indicate that p53 may participate in 
the mitotic checkpoint as a protective measure against abnormal chromosomal ploidization due 
to mitotic failure [185]. BUBR1 directly interacts with and phosphorylates p53 at Ser15 and 
Ser46 residues [185]. Moreover, activation by phosphorylation of ATM at Ser1981 in response 
to spindle damage also stabilizes p53 during M phase, enforcing the SAC [186, 187]. Activated 
p53 in the arrested cells acts post-mitosis to eliminate cells with chromosome aberrations and 
polyploidy [185]. Missense mutations in p53, found in about 50 percent of human cancers, result 
in increased risk of DNA damage, errors in mitosis, and suppression of apoptosis [188, 189]. 
Moreover, mutations also occur in the p53 DNA binding domain, indicating that its activity as a 
transcription factor is pivotal for cancer suppression [190-192]. How this activity could function 
on condensed mitotic chromosomes is not clear, but it may determine the fate of cells following 
exit from mitosis. 
We previously reported the identification of synthetic small molecule inhibitors that 
dramatically enhanced colon cancer cell death strictly in the presence TNF and other death 
ligands [145, 193]. The most potent of this piperazine-class of compounds, 1-(3-chlorophenyl)-4-
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(2-ethoxybenzoyl)piperazine, referred to as AK301, was found to have activity in the low 
nanomolar range (EC50 ≈ 115 nM) [193]. To gain insight into the mechanism of apoptosis in 
AK301-arrested cells, we studied the mitotic arrest state of AK301-treated cells in HCT116 cells. 
HCT116 cells differ from previously studies HT29 cells in a number of ways.. First, HCT116 
cells are MLH1-deficient and exhibit weakened G2/M checkpoint [194]. Importantly, these cells 
have normal p53 tumor suppressor gene. Here, we show that apoptosis in HCT116 cells can be 
activated in a death ligand-independent manner, by removing AK301 from medium and 
releasing the cells from mitotic arrest. We also demonstrate that this mitosis-to-apoptosis 
transition requires a reversible mitotic arrest by AK301, unlike other mitotic arrest agents that 
induce a more permanent mitotic arrest. Finally, we show that cancer cells treated with AK301 
arrest at a mitotic state that induced high levels of ATM activation and p53 stabilization relative 
to other mitotic arrest agents tested. The activation of p53 during mitosis culminates in an 
apoptotic response in cells following AK301 withdrawal.  We propose that AK301 represents a 
novel class of compounds that will be beneficial for understanding how pro-apoptotic signaling 
via ATM-p53 pathway can be activated during mitosis for efficient apoptosis in cancer cells. The 
pathways targeted by AK301 may ultimately find therapeutic applications. 
 
4.3. Materials and Methods 
4.3.1. Cell Culture 
HT29 and HCT116 colon cancer cell lines were obtained from the American Type 
Culture Collection (Manassas, VA). HT29 and HCT116 cell lines were cultured in McCoy’s 5A 
medium, with 10% fetal bovine serum, non-essential amino acids and antibiotic/antimycotic 
(Life Technologies, Guilford, CT). Immortalized primary colon cell lines YAMC and IMCE 
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were a gift of Dr. R Whitehead (Vanderbilt University, Nashville, TN). YAMC and IMCE cells 
were cultured in RPMI medium containing 5% fetal bovine serum, non-essential amino acids, 
antibiotic/antimycotic, insulin-transferrin-selenium (Life Technologies), and 5 units of murine 
gamma interferons. The cells were grown at 33°C. AK301 was synthesized from compounds 
obtained from the ChemBridge DIVERSetTM library (San Diego, CA). Colchicine and 
Vincristine, and BI 2536 were obtained from Sigma Aldrich (St. Louis, MO), Acros Organics 
(Pittsburgh, PA), and Selleck Chemicals (Houston, TX), respectively. Drug treatments were 
performed approximately 24 h after passage for 16 h, unless otherwise indicated. TNF was 
obtained from Pierce Protein Research Products (Rockford, IL). 
 
4.3.2. Immunofluorescence microscopy 
Cells cultured on coverslips were fixed with 4% paraformaldehyde at room temperature 
or 100% ice cold methanol at 4°C and then permeabilized with 0.5% Triton X-100 in PBS. Cells 
were blocked in 5% serum (in PBS) and then incubated with primary antibody (in 5% serum) on 
shaker for 1 h at room temperature against phosphohistone H3 Ser 28 (sc-12927, Santa Cruz 
Biotechnology, Santa Cruz, CA), β-tubulin (E7 monoclonal antibody, Developmental Studies 
Hybridoma Bank), or cleaved caspase-3 (Asp175, Cell Signaling). Appropriate secondary 
antibodies (Molecular Probes, Life Technologies or Jackson ImmunoResearch, West Grove, PA) 
were used for 45 min incubation. Nuclei were visualized using DAPI (5 μg/ml in PBS; DI306, 
Life Technologies). Coverslips were mounted on slides using ProLong Gold Antifade Reagent 
(Life Technologies). Images were acquired using Nikon A1R Confocal Microscope (version 
2.11, Nikon Instruments Inc.) and NIS-Elements Advanced Research Software (version 4.13.01, 
build 916, Nikon Instruments Inc.). Quantification of immunostaining was performed using 
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ImageJ image analysis software (http://rsb.info.nih.gov/ij) as previously described [88]. 
Following background subtraction and image stacking, both DAPI and immunofluorescence 
images were merged. Image brightness and contrast was modified with Adobe Photoshop 
software CC 2014 (Adobe Systems).  
 
4.3.3. Live cell imaging 
Cells were plated into 8-well chamber plates (NuncTM Lab-Tek®, Waltham, MA) and 
treated with compounds for 16 hrs. In the case of HT29 cells, drugs were replaced with 
SP600125 for 2 hrs, followed by fresh medium. The Andor iQ live cell imaging software 
(Oxford Instruments, Belfast, UK) with Clara Interline CCD or iXon EMCCD camera (Oxford 
Instruments) was used to image cells. Micro-Manager© (https://www.micro-manager.org) was 
used as acquisition controller. Images were processed and corrected using ImageJ image analysis 
software (http://rsb.info.nih.gov/ij). 
 
4.3.4. Flow cytometry and cell cycle analysis 
Cells were stained for γH2AX using the protocol described above for 
immunofluorescence staining. Briefly, cells were fixed with 4% PFA, permeabilized with 0.1% 
Triton X-100, and blocked with 5% donkey serum. Cells were then incubated with γH2AX 
antibody (sc-101696, Santa Cruz Biotechnology) followed by incubation with Alexa Fluor® 488 
secondary antibody (Life Technologies). Cells were then harvested using trypsin-EDTA for 15 
min at 37°C and washed once with PBS. Propidium iodide (30 µg/ml) was added to the cells 
prior to filtration through 35 µm cell strainer tubes. Cell were promptly analyzed by flow 
cytometry. 
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For cell cycle analyses, cells were analyzed for DNA content by ethanol fixation and 
staining with propidium iodide as previously described [89]. Cells were harvested using trypsin-
EDTA, centrifuged at 1000 X g for 10 min and resuspended in 500 μl of cold saline GM. Cells 
were washed once with 1X PBS and then fixed for at least 2 hrs at -20°C in 3X volumes of cold 
100% ethanol while vortexing. Cells were then pelleted and washed once with PBS containing 5 
mM EDTA. Pelleted cells were stained with 30 μg/ml propidium iodide (Molecular Probes, Life 
Technologies Corp.) and 0.3 mg/ml RNase A (Sigma-Aldrich, St. Louis, MO) in 500 μl PBS 
solution for 40 min in dark at RT. The stained cells were filtered through 35 μm cell strainer 
tubes (BD Biosciences, San Jose, CA). All flow cytometric analyses were performed on 
FACSCalibur (BD Biosciences) using Cell Quest software (BD Biosciences). The data were 
analyzed using FlowJo (v10, TreeStar Inc., Ashland, OR). 
 
4.3.5. Caspase-3 assay 
Caspase-3 activity was determined as previously described [145]. Cells were collected, 
centrifuged at full speed, and washed once with PBS. Pelleted cells were lysed by two rounds of 
freeze-thaw in lysis buffer containing 10 mM Tris-HCl (pH 7.5), 0.1 M NaCl, 1 mM EDTA, and 
0.01% Triton X-100 and centrifuged at 10,000 X g for 5 min. The assays were performed on 96 
well plate by mixing 50 μl of lysis supernatant with 50 μl of 2X reaction mix (10 mM PIPES pH 
7.4, 2 mM EDTA, 0.1% CHAPS, 10 mM DTT) containing 200 nM of the fluorogenic substrate 
Acetyl-Asp-Glu-Val-Asp-7-Amino-4-methylcoumarin (DEVD-AMC; Enzo Life Sciences). The 
fluorescence was quantified at the start of the reaction and after 30 min. Protein concentrations 
were determined using CBQCA Protein Quantitation Kit (Life Technologies). Caspase activity 
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was determined by dividing the change in fluorescence by total protein content of the reaction 
mixture.  
 
4.3.6. Western blot 
RIPA buffer was used for total protein extraction and NP-40 buffer was used for 
membrane protein extraction. 20 μg of protein was denatured under reducing conditions and 
separated on 10% polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA) and transferred to 
nitrocellulose by voltage gradient transfer. The resulting blots were blocked with 5% (w/v) non-
fat dry milk in PBS + 0.1% (v/v) Tween-20. Specific proteins were detected with appropriate 
antibodies using SignalFireTM Elite ECL Reagent (Cell Signaling Technology). Immunoblotting 
antibodies were cleaved caspase-8 (18C8, Cell Signaling Technology), p53 (OP03, Calbiochem, 
Germany), p-p53, ATM (2873, Cell Signaling Technology), and p-ATM Ser1981 (13050 Cell 
Signaling Technology) 
 
5.3.6. Statistical analyses 
One-way analysis of variance (ANOVA) was used when comparing two groups with 
Tukey’s post hoc test. For more than two groups, two-way ANOVA was used with Bonferroni 
correct. Significance was calculated at an alpha of 0.05. 
 
4.4. Results 
4.4.1. AK301-arrested cells show increased caspase-3 activity 
To compare the mitotic arrest-inducing ability of AK301, we tested various 
pharmacological agents, including microtubule inhibitors (colchicine and vincristine), and a 
100 
PLK1 inhibitor (BI2536) for their ability to induce mitotic arrest. HCT116 colon cancer cells 
were treated with either 250 nM or 500 nM of each of these agents. Flow cytometric analysis of 
propidium iodide (PI)-stained cells was performed to assess the DNA content of the cells. All of 
the agents tested were able to induce over 80% of mitotic arrest (P < 0.0001) (Figure 4.1A). To 
examine the relationship between induced mitotic arrest and sensitivity, we tested these agents 
for their ability to induce capase-3 activation in HCT116 cells, using a DEVD-AMC fluorogenic 
substrate. All agents were tested at 500 nM. As shown in Figure 4.1B, of the four mitosis-
arresting agents, only AK301 (P < 0.0001) and BI2536 (P < 0.05) were able to induce significant 
levels of caspase-3 activity. These results demonstrate a close relationship between the phase of 
mitotic arrest and cell sensitivity. 
  
4.4.2. AK301 withdrawal enhances apoptotic response in HCT116 cells 
Mitotic inhibitors can bind reversibly or irreversibly to their target. To better understand 
the nature of AK301’s interaction with its proposed target, β-tubulin, we withdrew AK301 from 
arrested HCT116 cell culture and monitored their progression through the cell cycle for 24 hours 
post release. Flow cytometric analysis performed at 3, 6, 12 and 24 hours post AK301 
withdrawal showed the appearance of sub G1 population in the cells released from AK301 arrest 
as early as 3 hours after release (Figure 4.2B). However, cells arrested with AK301 showed little 
to no apoptosis during the 24 hour period (Figure 4.2A). These data demonstrate that AK301 
may bind reversibly to microtubules and that withdrawal of the drug enhances the sensitivity of 
HCT116 cells to apoptosis. 
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Figure 4.1. AK301 and BI2536 induce the highest levels of caspase-3 activation. 
(A) HCT116 cells were treated with the indicated concentrations of AK301, colchicine, 
vincristine (microtubule inhibitors), and BI2536 (PLK1 inhibitor) for 16 h. Cells were fixed and 
stained with propidium iodide (PI) and analyzed by flow cytometry. All four drugs induced 
significantly high levels of G2/M arrest at both drug concentrations (P < 0.0001). (B) HCT116 
cells were treated with 500 nM of each of the drug for 16 h. Cell lysates were prepared and tested 
for levels of caspase-3 activity using DEVD-AMC fluorogenic assay and protein concentration 
with CBQCA assay. AK301 (**P < 0.0001) and BI2536 (*P < 0.05) induced significantly higher 
levels of caspase-3 activation in HCT116 cells. 
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Figure 4.2. Release from AK301-induced mitotic arrest enhances apoptosis in HCT116 
cells. 
(A) HCT116 cells were treated with 500 nM of AK301 for 16 hrs. Subsequently, AK301 was (B) 
removed and the cells were allowed to grow in fresh medium for 3, 6, 12, and 24 hrs following 
AK301 withdrawal. For the arrested cells, AK301 was added to the medium. Cells were 
harvested at the indicated times post AK301 treatment. Consistent with Figure 1B, flow 
cytometric analysis of the DNA content of AK301-arrested cells showed significant increase in 
sub G1 population. However, removal of AK301 enhanced sub G1 population significantly at 
each of the indicated times post-withdrawal.  
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We compared the effect of AK301 withdrawal to that of colchicine, which forms a tight 
complex with β-tubulin. HCT116 cells treated with 500 nM of either AK301 or colchicine were 
analyzed at 6, 8, and 10 hours post drug withdrawal. As shown in Figure 4.3A, AK301-treated 
cells showed appreciably greater percentage of sub G1 population than cells treated with 
colchicine (Figure 4.3B). Colchicine-treated cells showed little to no sub G1 population. In 
addition, AK301-treated cells showed recovery from mitotic arrest into the interphase unlike 
colchicine-treated cells. These data suggest a reversibility of AK301 action in arresting cells in 
mitosis. 
 
4.4.3. Arrested cells exiting mitosis are more prone to apoptosis 
To determine the association between the reversibility of mitotic arrest and apoptosis, we 
analyzed colchicine, vincristine, and BI2536. HCT116 cells treated with these agents were 
subsequently allowed to exit mitosis for 8 hours prior to flow cytometric analysis of DNA 
content. Consistent with Figure 4.1A, all the agents tested induced high levels of mitotic arrest, 
as indicated by the G2/M population (Figure 4.4A). Cells released from AK301- and BI2536-
induced arrest showed a significant decrease in the G2/M population (P < 0.0001) (Figure 4A). 
Moreover, subsequent analysis of sub G1 population indicated a significant increase in AK301-
treated cells. BI2536, however, was not effective at sensitizing cells to apoptosis. Colchicine and 
vincristine did not show any significant increase in sub G1 population (Figure 4B). These data 
suggest that a reversible mitotic arrest of cancer cells may allow them to exit mitosis 
prematurely, resulting in apoptosis. 
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Figure 4.3. AK301 withdrawal induces significantly more apoptosis than that with 
colchicine withdrawal.  
HCT116 cells were treated with 500nM of either (A) AK301 or (B) colchicine for 16 hrs. Cells 
were allowed to grow in fresh medium for indicated times. Flow cytometric analysis of DNA 
content showed that both AK301 and colchicine arrested HCT116 cells in G2/M phase of the cell 
cycle. However, upon drug withdrawal, AK301 resulted in a significantly greater increase in sub 
G1 population than those arrested with colchicine at each of the indicated times. Moreover, 
AK301-treated cells showed a time-dependent increase in sub G1 population following drug 
withdrawal. 
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Figure 4.4. AK301-treated cells exiting mitosis following drug withdrawal undergo 
apoptosis. 
HCT116 cells treated with 500 nM of each of the indicated drug for 16 h. Cells continued to 
grow in AK301-containing medium or drug-free medium for 8 h. (A) Flow cytometric analysis 
of the DNA content showed that all compounds induced a G2/M arrest, consistent with Figure 
1B. Following release of the drugs, only AK301 treated cells showed a significant decrease in 
G2/M population (*P < 0.0001). (B) Analysis of the sub G1 population showed that only 
withdrawal of AK301 induced a significant increase in sub G1 population, but not other mitotic 
arrest compounds (*P < 0.0001). 
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4.4.4. AK301-treated cells show microtubule recovery after AK301 withdrawal 
To gain insight into AK301’s mechanism of action, we visualized differences in 
microtubule morphologies after treatment with AK301 and colchicine. HCT116 cells were 
allowed to exit mitosis after treatment with AK301 or colchicine. Arrested cells and post-drug 
withdrawal released cells were immunostained for β-tubulin and phospho-histone H3 (p-HH3), a 
chromosomal marker of mitosis. Consistent with the previous results, both AK301 and 
colchicine induced a mitotic arrest as indicated by an increase in the number of p-HH3 positive 
cells. Interestingly (data not shown), cells released from colchicine retained high mitotic index 
(condensed chromatin), in contrast to a low mitotic index in cells released from AK301-induced 
arrest (Figure 4.5B). 
Both the agents induced disassembly of microtubule networks as anticipated (Figure 
4.5A). Consistent with our previous findings, AK301 induced the least disruption of microtubule 
networks and exhibited the formation of multiple microtubule organizing centers (MTOCs). 
Colchicine-treated cells, however, showed a complete breakdown of microtubule networks. After 
drug withdrawal, AK301-treated cells showed recovery of microtubule networks, whereas 
colchicine-treated cells showed little to no recovery (Figure 4.5B). Together, these data indicate 
a more reversible mitotic arrest by AK301. We propose that this reversibility may play an 
important role in sensitizing colon cancer cells to apoptosis. 
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Figure 4.5. AK301 induces a more reversible mitotic arrest. 
(A) HCT116 cells treated with AK301 or colchicine were fixed, permeabilized, and 
immunostained for β-tubulin. Both AK301- and colchicine-treated cells disrupted the formation 
of microtubules. AK301 treatment resulted in the formation of multiple MTOCs. (B) Cells 
released from mitotic arrest induced by AK301 or colchicine were immunostained for phospho-
histone H3 Ser28 (green) and β-tubulin (red). Nuclei were counterstained with DAPI. 
Colchicine-treated cells show a higher proportion of cells stained with p-HH3 Ser28, whereas the 
proportion dropped after release from AK301-induced arrest. AK301-treated cells showed a 
normal bipolar assembly of microtubules after drug withdrawal, unlike colchicine. 
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4.4.5. Apc and p53 mutations enhance the sensitivity of HCT116 cells 
Apc, a crucial protein in Wnt signaling and microtubule growth, is lost in most colon 
cancers, including HCT116 cancer cells [195, 196]. To assess the effect of Apc mutation on 
AK301-induced apoptosis, Apc+/+ immortalized Young Adult Mouse Colonocytes (YAMCs) and 
Apc heterozygous (ApcMin/+) Immorto-Mouse Colonic Epithelial cells (IMCEs) were treated with 
500 nM of AK301 for 16 hours. Cells were allowed to exit mitosis in the absence of AK301 and 
cells were analyzed at 20, 30, and 40 hours post-release by flow cytometry as described above. 
As shown in Figure 4.6A, both cell lines showed an increase in sub G1 population, however, 
IMCEs showed a significantly higher sub G1 population over sub G1 in YAMCs at all sampling 
intervals. These data suggest that cells carrying microtubule-disruptive Apc mutations are more 
sensitive to the apoptotic inducing effects of AK301 compared to normal colon epithelial cells.  
One of the most important proteins in the apoptotic pathway is p53, which is mutated in 
50% of colon cancers [188]. To evaluate the role of p53 in AK301-induced apoptosis, we treated 
wild type (p53+/+) and p53 null (p53-/-) HCT116 colon cancer cells with AK301 and assessed the 
level of capase-3 activation using a DEVD-AMC fluorogenic assay. As shown in Figure 4.6B, 
wild type HCT116 cells treated with AK301 showed a significant increase in active caspase-3, 
consistent with previous experiments. Conversely, p53 null cells did not show a significant 
increase in caspase-3 activation after AK301 treatment. These data demonstrate that caspase-3 
activation and apoptosis progression in AK301-treated HCT116 colon cancer cells is p53 
dependent. 
To further evaluate the role of p53, we performed cell cycle analysis on both p53 wild 
type (p53+/+) and p53 null (p53-/-) HCT116 cells. Cells were treated with AK301 and 
subsequently released as described above, followed by flow cytometric analysis. Consistent with 
109 
previous results, the wild type cells were more sensitive than their p53 null counterparts. 
Moreover, wild type cells showed a significant increase in sub G1 population upon exit from 
AK301-induced arrest (P < 0.0001), in agreement with previous results. Conversely, no 
significant increase in sub G1 was observed between control p53 null cells and p53 null cells 
after AK301 withdrawal (Figure 4.6C). 
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Figure 4.6. Apoptotic inducing ability of AK301 is p53-dependent and enhances the 
sensitivity of Apc mutant IMCE cells for apoptosis. 
(A) Apc+/+ YAMCs and ApcMin/+ IMCE cells were treated with 500 nM of AK301 for 16 h, 
followed by a release from arrest for 40 h. Cells were harvested at the indicated times post-
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release and their DNA content was analyzed by flow cytometry for the appearance of sub G1 
population. AK301 induced significantly greater apoptosis in Apc mutant IMCE cells. The 
apoptosis effect was enhances in IMCE cells after AK301 withdrawal (**P < 0.0001). hpr: hours 
post release (B) p53+/+ and p53-/- HCT116 colon cancer cells were treated with AK301 and 
caspase-3 activity was assessed using DEVD-AMC assay. AK301 induced significantly higher 
activation of caspase-3 in p53+/+ cells compared to their p53-/- counterparts (**P < 0.0001). (C) 
p53+/+ and p53-/- HCT116 cells were treated with AK301, followed by release from mitotic 
arrest. Cells were analyzed by flow cytometry for sub G1 population. AK301 induced a 
significantly greater arrest in p53 wildtype cell compared to p53 null cells. The sub G1 
population of p53+/+ cells was significantly enhanced when the cells were allowed to exit mitosis 
(**P < 0.0001).  
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4.4.6. ATM-dependent p53 activation is required for mitotic exit, but not for γH2AX activation 
To determine whether γH2AX was activated in response to DNA damage in HCT116 
cells, we immunostained for γH2AX phosphorylation at Ser139 in cells arrested with AK301, 
colchicine, vincristine, or BI2536. Flow cytometric analysis was performed to determine the 
association between mitotic arrest state and γH2AX phosphorylation. AK301-treated cells 
showed the highest percentage γH2AX positive cells (P < 0.0001) compared to other mitotic 
inhibitors tested (P < 0.05), indicated by cells in the second quadrant (Q2) of the dot matrix plot 
(Figure A5A). Quantification of γH2AX+ cells is shown in Figure A5B. Moreover, only the 
AK301 mitosis-arrested cells demonstrated phosphorylation of H2AX. To determine if the 
γH2AX activation was p53-dependent, we tested p53+/+ and p53-/- HCT116 cells for activation of 
γH2AX in AK301-arrested cells and cells released from mitotic arrest. As shown in Figures 4.7A 
and 4.7B, both wild type and null cells exhibited γH2AX activation, suggesting a p53-
independent mode of activation. However, upon AK301 withdrawal, p53+/+ cells showed a 
significant decrease in γH2AX staining compared to their p53 null cell counterparts. Moreover, 
we compared γH2AX activation in cells treated with AK301 and other mitotic arrest inducing 
agents (colchicine, vincristine, and BI2536). As shown in Figures 4.7C and 4.7D, AK301-
treatment induced γH2AX activation in a significantly greater proportion of cells compared to 
other mitotic arrest agents. Together, these data suggest that γH2AX activation in AK301-
arrested cells is a p53-independent process, but induction of apoptosis following release from 
mitosis requires p53 activity. 
Stabilization of p53 and γH2AX is an ATM-dependent process [187]. To investigate the 
possible role of ATM in the activation of p53 and γH2AX, we prepared lysates of HCT116 cells 
treated with AK301 for 18 hrs and those from which drug was withdrawn for 4 and 6 hrs and 
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immunoblotted for p-p53 Ser15, MDM2, and ATM phosphorylation at Ser1981. As shown in 
Figure 4.7C, AK301-treated cells showed phosphorylation of ATM Ser1981. This was 
accompanied by phosphorylation of p53 Ser15 and activation of MDM2. Release of HCT116 
cells from AK301 enhanced the activity of ATM, p53, and MDM2. These data suggest that p53 
activation is ATM-dependent. Activation of ATM increases after treatment with AK301, but is 
further enhanced after release of AK301. 
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Figure 4.7. ATM-dependent stabilization of p53 in AK301-treated is enhanced after mitotic 
release. 
(A)  p53+/+ and p53-/- HCT116 cells were treated with 500 nM of AK301 for 16 h followed by 
drug withdrawal. Cells were fixed with PFA and stained for γH2AX and PI counterstain was 
used to stain DNA. Dot matrix plots (quadrant 2, Q2) show that AK301 induced γH2AX 
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regardless of p53 mutation status. Removal of AK301 significantly reduced γH2AX staining in 
p53 wildtype, but not p53 null cells. (B) Quantification of γH2AX staining in cells staining with 
PI (Q2) (*P < 0.0001). (C) γH2AX staining and flow cytometric analysis of p53+/+ HCT116 cells 
treated with the indicated mitotic arrest agents – AK301, colchicine, vincristine, and BI2536. 
Treated cells were stained as described above (D) Quantification of γH2AX positive cells in 
response to each of the treatments in (D) above. AK301-treated HCT116 cells showed a 
significantly greater proportion of cells with γH2AX activation (*P < 0.0001). (E) p53+/+ 
HCT116 cells were treated with AK301, followed by growth in fresh medium. Total protein was 
isolated by RIPA extraction after AK301 treatment and 4 and 6 hrs drug release from mitotic 
arrest. Immunoblot analysis shows phosphorylation of ATM at Ser1981, stabilization of p53 (p-
p53 Ser15) and stabilization of MDM2 after AK301 treatment. The phosphorylation of ATM and 
p53 as well as activation of MDM2 was greatly enhanced, in a time-dependent manner, after 
releasing cells from mitotic arrest. β-actin was used as a loading control. 
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4.5. Discussion 
We previously reported the identification of small molecule microtubule inhibitors that 
induced mitotic arrest in colon cancer cells and dramatically enhanced colon cancer cell death 
strictly in the presence of death ligands [145, 193]. Structure-activity relationship studies led to 
the identification of a more potent compound, AK301, with EC50 of 115 nM [193]. Moreover, 
we showed that these compounds reduced microtubule polymerization, unlike other microtubule 
inhibitors that completely abrogate microtubule polymerization [193]. The reduction in 
microtubule polymerization along with an increase in cell surface expression of TNFR1 led to 
apoptotic signaling in AK301-treated colon cancer cells. In this study, we show that AK301, in 
the absence of death ligands, is highly effective at inducing a mitosis-to-apoptosis transition 
following release from the mitotic arrest state. We also show that the activation of apoptosis is a 
p53-mediated process. Further, AK301 is able to induce the activation of ATM, which is 
necessary for p53 activation, ultimately resulting in a robust apoptotic response in cancer cells 
exiting mitosis (Figure 4.8). 
Mitotic checkpoints safeguard entry into and exit from mitosis [130]. Mutations in 
checkpoint kinases, such as those involved in the spindle assembly checkpoint (SAC) and DNA 
repair pathways, have been implicated in development of colon cancer [28, 40, 197-199]. Based 
on the in vitro microtubule disruptive activity of AK301, we anticipated that removal of AK301 
would restore bipolar spindle formation in arrested cells and that the cells would complete 
mitosis. Consistent with our previous studies [193], we showed that AK301 effectively arrested 
cells in mitosis at low nanomolar concentrations. Surprisingly, however, cells exiting mitosis 
after AK301 withdrawal were susceptible to apoptosis. Notably, release from AK301-induced 
mitotic arrest, but not from other mitotic inhibitors, resulted in apoptosis. These results suggest 
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that limited disruption of microtubules by AK301 allows the arrested cancer cells to reassemble 
microtubules and aberrantly exit mitosis. In addition, other labs have also shown that weakening 
of SAC and aberrant exit from mitosis results in effective apoptosis [179, 200-202]. Taken 
together, our findings suggest that cancer cells are vulnerable to mitotic slippage following 
AK301 withdrawal, which induces apoptosis in these cells. It would be of interest to determine 
whether these arrested cells complete mitosis and arrest at a post-mitotic checkpoint following 
drug withdrawal or they simply slip out of mitosis and undergo cell death pending activation of 
apoptotic signaling. Moreover, how these cells transition from an aberrant mitosis to apoptosis 
needs to be further investigated. 
APC mutations are frequently found in colon cancers and aid in tumor progression [195, 
203, 204]. It is thought to be one of the first genes mutated in colon carcinogenesis [205, 206], 
and its mutation leads to an increase in Wnt signaling [207, 208]. APC is also known to regulate 
spindle assembly during mitosis by stabilizing microtubule plus (growth) ends [195, 208]. 
Further, APC binds to and recruits end-binding protein 1 (EB1) to microtubule plus ends for 
stability [208], and is also involved in the activation of SAC by direct interaction with BUB1 and 
BUBR1 [209]. C-terminal truncating mutations of APC, most commonly found in colon cancers 
act in a dominant negative fashion to inhibit the function of wildtype APC protein [195, 204, 
210]. Since AK301 acts to reduce the polymerization of microtubules, we anticipated that 
AK301 withdrawal would selectively induce apoptosis in an Apc mutant mouse colonocyte cell 
line (IMCE). We found that ApcMin/+ IMCEs were more sensitive to AK301 treatment. This is 
likely due to the additive effect of microtubule disruption by AK301 in an Apc mutant cell line. 
In addition, exit from mitosis after AK301 withdrawal triggered apoptosis in Apc heterozygous 
IMCE cells, higher than that in Apc wildtype YAMCs. Note that unlike HCT116 cells, Apc 
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mutant IMCE cells lack a robust SAC, thus making it easier for arrested cells to aberrantly exit 
mitosis upon drug withdrawal. These data not only reinforce the requirement of mitotic slippage 
for an effective apoptotic response, but also demonstrate the specificity of AK301 in targeting 
APC mutant cells. 
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Figure 4.8. Proposed model for AK301’s mechanism of action. 
Treatment of cancer cells with AK301 results in a mitotic arrest with multiple MTOCs. AK301 
induces high levels of activated ATM, which stabilizes p53. Releasing cells from mitotic arrest 
by removal of AK301 induces apoptosis in cells via the p53 pathway.   
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Although our results and other studies have shown that p53 is not required for the 
activation of SAC and mitotic arrest [185, 211], it is required for activation of apoptosis in cells 
exiting mitosis [182, 212]. However, p53 localizes to the centrosomes during mitosis and 
displaced upon spindle damage [213, 214]. Considering the localization of p53 during mitosis 
and its role as a tumor suppressor, it is conceivable that p53 is activated in response to mitotic 
damage. In fact, the activity of p53 might act as a secondary fail safe mechanism to SAC during 
mitosis. In turn, the activation of p53 can result in apoptosis or a more permanent exit from cell 
division post-mitosis. p53 can be activated by several different kinases during mitosis [186, 215]. 
In contrast to a recent study that showed the requirement of both γH2AX and p53 activation for 
cell cycle arrest [216], our results suggested otherwise; AK301-induction of mitotic arrest was 
observed to be p53- and γH2AX-independent. However, our results indicated that p53 activation 
is required for an effective mitosis-to-apoptosis transition after releasing cells from mitosis. 
γH2AX activation, in this case, may be induced by the activation of a kinase, ataxia 
telangiectasia mutated (ATM), in a DNA damage-independent manner. The role γH2AX 
activation, if any, during or after mitotic arrest, however, is unclear. 
To address the DNA damage-independent activation of p53 during mitosis, we 
investigated the possible involvement of ATM. Immunoblot analysis showed the 
phosphorylation of ATM at Ser1981, suggesting a DNA damage-independent mode of ATM 
activation, resulting in the activation of p53. ATM activation, in turn, can be attributed to defects 
in microtubule function. Studies have shown that ATM is activated by default (by 
phosphorylation at Ser1981) in cells undergoing mitosis and localizes to the centrosomes [217]. 
Activation of SAC displaces ATM, which localizes throughout the cytoplasm and activates p53 
[187]. We propose that defects in mitotic spindle assembly, induced by AK301, result in high 
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levels of ATM-dependent p53 activation, which ultimately leads to apoptosis in cells that exiting 
mitosis [218, 219]. 
 Microtubule disruptors have been used for decades as the clinical treatment of some 
cancers [220]. Vincristine and its derivatives are used in the treatment of cancers, such as B-cell 
lymphoma [221]. These drugs are successful at diminishing tumor size but their general toxicity 
results in undesirable side effects for patients. Therefore, there is an urgent need to identify 
therapeutic compounds that specifically target cancer cells. In this study, we illuminated the 
mechanism of action of AK301 and provide a paradigm for the activation of apoptosis in both 
cancer cells as well as non-transformed APC mutant colon cancer cells. However, further 
investigation is required to identify targets of AK301 and explore in detail the ability of AK301 
in inducing mitotic arrest and efficient apoptosis following release from mitosis. Unlike other 
microtubule inhibitors, AK301 may target the microtubule defects associated with an APC 
mutation more directly. Understanding the vulnerabilities of cancer cells may ultimately help in 
the development of therapeutics that effectively and specifically target these cells for 
elimination. 
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CHAPTER 5 
Targeting APC-/- mutant cells for apoptosis via microtubule disruption by AK301 
 
5.1. Abstract 
Adenomatous polyposis coli (APC) is a tumor suppressor which is mutated in a majority 
of colorectal cancers. The role of APC in Wnt signaling is well understood. However, the effect 
of APC mutations on microtubule polymerization and stability are less well studied. Using Apc+/+ 
and ApcMin/+ mouse colonocyte cell lines, we show that APC heterozygous mutant cells exhibit 
microtubule defects, especially during mitosis. In addition, we show that Apc mutant cells are 
sensitive to a small molecule microtubule disrupting agent, AK301, we previously identified. In 
the presence of AK301, Apc mutant colonocytes display microtubule defects and form multiple 
microtubule organizing centers (MTOCs). Further, we show that Apc mutant colonocytes 
undergo apoptosis upon AK301 treatment. Expression of APC C-terminus truncated protein 
(APCΔC) in human HEK293 cells showed similar defects in microtubule networks and bipolar 
spindle formation, which were aggravated by AK301 treatment. Understanding the mechanisms 
by which cells cope with APC-associated microtubule defects may help identify novel targets 
and aid in the development of specific and potent chemotherapeutic and chemopreventive agents. 
 
5.2. Introduction 
Colon cancer begins in a single cell with a genetic mutation that gives that cell a growth 
advantage [206]. From there, a series of mutations in tumor suppressor genes and oncogenes 
cause a colon cancer to develop and progress [222, 223]. Genes in the Wnt signaling pathway are 
critical for the initiation and progression of colon cancer [224-226]. According to Vogelstein’s 
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model for the development of colorectal cancer, the initial genetic alteration in most colon 
cancers is the loss of function of the tumor suppressor gene, adenomatous polyposis coli (APC) 
[206]; APC mutations are found in 80-90 percent of colon cancers [40, 203]. APC is involved in 
normal intestinal development and influences a variety of cellular processes [226, 227]. Loss of 
APC function results in intestinal neoplasia in both mice and humans [228]. Mutations in APC 
deregulate Wnt signaling and lead to stabilization and nuclear translocation of β-catenin, which 
results in aberrant transcriptional activation of TCF/LEF target genes [207, 229]. However, APC 
also plays a role in microtubule polymerization and stabilization, and microtubule anchoring to 
cellular attachment sites to establish cell polarity [195, 230-232]. The effect of APC mutations on 
microtubule dynamics and assembly has been proposed to participate in cell transformation, 
including the acquisition of the chromosomal instability (CIN) phenotype that can drive cancer 
progression [233-235]. Although the cancer promoting effects of an APC mutation are well 
established, there is some evidence that this defect can render mutant cells sensitive to specific 
treatments [236]. Here, we focus on the potential effectiveness of targeting the microtubule and 
mitotic defects associated with an APC mutation.   
Proper spindle formation during mitosis is crucial to ensure proper alignment and 
segregation of chromosomes [168]. Microtubules are highly dynamic at their plus ends; their 
stability at the plus ends is largely regulated by EB1 and APC [169, 237, 238]. Binding of APC 
to the carboxy-terminus of EB1 enhances the ability of EB1 to bind polymerized microtubules, 
suggesting that APC may help to stabilize microtubules, and therefore, cell polarity 
establishment, and chromosome capture and segregation during mitosis [230, 239, 240]. 
Moreover, APC also binds directly to the plus ends of growing microtubules and has been found 
to be localized at the kinetochore-microtubule complexes [230, 241]. Recent studies indicate that 
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expression of truncated forms of APC dominantly compromises microtubule dynamics [242] and 
kinetochore-microtubule attachments [208, 243], indicating that the influence of APC mutation 
on cancer progression occurs even before both alleles are mutated. Aberrant mitosis and failed 
cytokinesis have been observed in normal tissue of ApcMin/+ mice [244-246]. Although colon 
cancer cells cope with the loss of APC function, it is unclear how they compensate for this loss. 
However, loss of APC function may be an “Achilles heel” of a mutated cell; we will explore this 
possibility in this chapter. 
In this study, we demonstrate that ApcMin/+ heterozygous cells with truncated APC have 
defects in their microtubule networks. Moreover, ApcMin/+ cells were found to be sensitive to 
microtubule disruption by a piperazine-based agent, 1-(3-chlorophenyl)-4-(2-
ethoxybenzoyl)piperazine, referred to as AK301, previously identified for its ability to induce 
mitotic arrest and apoptosis in colon cancer cells. Expression of the C-terminus truncated APC 
(APCΔC) in HEK293 cells showed effects on microtubule formation similar to those observed 
with ApcMin/+ IMCE cells. Further, aurora kinase A was found to be mislocalized in APC mutant 
cells was observed to be particularly sensitive to AK301 treatment, consistent with a more severe 
disruption in the structure and/or composition of the spindle assembly apparatus. Understanding 
how APC mutations affect colonic epithelial cells could provide insight into early cellular 
changes in colon cancer develop, which may prove useful in colon cancer prevention. 
 
5.3. Materials and Methods 
5.3.1. Cell culture, transfections, and preparation of stable cell lines 
YAMC and IMCE cell lines were a gift from Dr. Robert Whitehead (Vanderbilt 
University, Nashville, TN) [247]. YAMC and IMCE cells were cultured in RPMI medium 
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containing 5% fetal bovine serum, non-essential amino acids, antibiotic/antimycotic, insulin-
transferrin-selenium (Life Technologies), and 5 units of murine gamma interferons. The cells 
were grown at 33°C in 5% CO2. HEK293 cells were a gift from Dr. Antonio Garmendia 
(University of Connecticut, Storrs, CT). HEK cells were cultured in DMEM, containing 10% 
fetal bovine serum, non-essential amino acids, and antibiotic/antimycotic. The cells were grown 
at 37°C in 5% CO2. Cells were transfected with either pEGFP-C1 or APC-containing pEGFP-C1 
plasmid using Lipofectamine® 3000 reagent (Life Technologies) following manufacturer’s 
instructions [248]. Briefly, cells were placed in reduced serum OptiMEM. 1 µl Lipofectamine 
3000 reagent was diluted in 25 µl of OptiMEM per well for a 24-well plate. 1 µg of plasmid per 
well was diluted in 25 µl of OptiMEM and 1 µl of P3000 reagent per well was added. Diluted 
Lipofectamine and plasmids were mixed and allowed to sit for 20 min before adding to cells. 
Cells were incubated overnight at 37°C. For preparation of stable cell lines, transfected cells 
were grown in the presence 400 µg/ml of geneticin for two weeks. Remaining cells were plated 
in a 100 mm dish at low density and colonies were allowed to form. Single colonies expressing 
GFP were transferred to each well of a 24-well plate in the absence of geneticin. Extracts from 
these cells were tested for the presence of APCΔC-GFP by western blot. AK301 was obtained 
from ChemBridge DIVERSetTM library (San Diego, CA). Drug treatments were performed 
approximately 24 h after passage for 16 h, unless indicated otherwise. TNF was obtained from 
Pierce Protein Research Products (Rockford, NJ). 
  
5.3.2. Generation of constructs expressing GFP-APCΔC 
End-sequenced human APC cDNA clones were obtained from TransOmic (TCHS1003, 
Huntsville, AL). A pair of primers were designed with a mutant base (T to A) in the reverse 
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primer. Primers 5’-GGGG CTCGAGATGGCTGCAGCTTCATATGAT-3’ (forward) and 5’- 
GGGGGTCGACCTAACTTCTGTC TTTCTCAGA-3’ (reverse), which contain non-
homologous sequences at each 5’ end that were used to add SalI and XhoI sites of pEFGP-C1 
plasmid. The primers were used to amplify the short APC fragment using a high fidelity Pfu 
polymerase. Amplification was confirmed by agarose gel electrophoresis, and PCR products 
were purified with a QIAquick® PCR Purification Kit (28104, Qiagen, Valencia, CA). Purified 
samples were sequenced using ABI Prism Big Dye Terminator Cycle Sequencing (Perking-
Elmer Applied Biosystems, Carlsbad, CA). The resulting APC fragment was ligated to pEGFP-
C1 plasmid by Gibson Assembly Kit (New England Biolabs, Ipswich, MA). The plasmid DNA 
was amplified in the E. coli strain DH5α (Life Techologies) and extracted using QIAGEN® 
Plasmid Midi Kit (12143, Qiagen) following manufacturer’s instructions. Purified plasmid was 
resuspended in nuclease-free water and checked by agarose gel electrophoresis and OD readings 
at 260 and 280 nm. The final plasmid was sequenced as described above to ensure no mutations 
were introduced by PCR amplification. 
 
5.3.3. Immunoflorescence microscopy 
Cells cultured on coverslips were fixed with 4% paraformaldehyde at room temperature 
or 100% ice cold methanol at 4°C and then permeabilized with 0.5% Triton X-100 in PBS. Cells 
were blocked in 5% serum (in PBS) and then incubated with primary antibody (in 5% serum) on 
shaker for 1 h at room temperature against β-tubulin (E7 monoclonal antibody, Developmental 
Studies Hybridoma Bank) or aurora kinase A (610938, BD Biosciences, San Jose, CA). 
Appropriate secondary antibodies (Molecular Probes, Life Technologies, Guilford, CT or 
Jackson ImmunoResearch, West Grove, PA) were used for 45 min incubation. Nuclei were 
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visualized using DAPI (5 μg/ml in PBS; DI306, Life Technologies). Coverslips were mounted 
on slides using ProLong Gold Antifade Reagent (Life Technologies). Images were acquired 
using Nikon A1R Confocal Microscope (version 2.11, Nikon Instruments Inc.) and NIS-
Elements Advanced Research Software (version 4.13.01, build 916, Nikon Instruments Inc.). 
Quantification of immunostaining was performed using ImageJ image analysis software 
(http://rsb.info.nih.gov/ij) as previously described [88]. Following background subtraction and 
image stacking, both DAPI and immunofluorescence images were merged. Image brightness and 
contrast was modified with Adobe Photoshop software CC 2014 (Adobe Systems). 
 
5.3.4. Flow cytometry and cell cycle analysis 
Cells were stained for γH2AX using the protocol described above for 
immunofluorescence staining. Briefly, cells were fixed with 4% PFA, permeabilized with 0.1% 
Triton X-100, and blocked with 5% donkey serum. Cells were then incubated with γH2AX 
antibody (sc-101696, Santa Cruz Biotechnology) followed by incubation with Alexa Fluor® 488 
secondary antibody (Life Technologies). Cells were then harvested using trypsin-EDTA for 15 
min at 37°C and washed once with PBS. Propidium iodide (30 µg/ml) was added to the cells 
prior to filtration through 35 µm cell strainer tubes. Cell were promptly analyzed by flow 
cytometry. 
For cell cycle analyses, cells were analyzed for DNA content by ethanol fixation and 
staining with propidium iodide as previously described. Cells were harvested using trypsin-
EDTA, centrifuged at 1000 X g for 10 min and resuspended in 500 μl of cold saline GM. Cells 
were washed once with 1X PBS and then fixed for at least 2 hrs at -20°C in 3X volumes of cold 
100% ethanol while vortexing. Cells were then pelleted and washed once with PBS containing 5 
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mM EDTA. Pelleted cells were stained with 30 μg/ml propidium iodide (Molecular Probes, Life 
Technologies Corp.) and 0.3 mg/ml RNase A (Sigma-Aldrich, St. Louis, MO) in 500 μl PBS 
solution for 40 min in dark at RT [89]. The stained cells were filtered through 35 μm cell strainer 
tubes (BD Biosciences, San Jose, CA). All flow cytometric analyses were performed on 
FACSCalibur (BD Biosciences) using Cell Quest software (BD Biosciences). The data were 
analyzed using FlowJo (v 10, TreeStar Inc., Ashland, OR). 
 
5.3.5. Caspase-3 assay 
Caspase-3 activity was determined as previously described [145]. Cells were collected, 
centrifuged at full speed, and washed once with PBS. Pelleted cells were lysed by two rounds of 
freeze-thaw in lysis buffer containing 10 mM Tris-HCl (pH 7.5), 0.1 M NaCl, 1 mM EDTA, and 
0.01% Triton X-100 and centrifuged at 10,000 X g for 5 min. The assays were performed on 96 
well plate by mixing 50 μl of lysis supernatant with 50 μl of 2X reaction mix (10 mM PIPES pH 
7.4, 2 mM EDTA, 0.1% CHAPS, 10 mM DTT) containing 200 nM of the fluorogenic substrate 
Acetyl- Asp-Glu-Val-Asp-7-Amino-4-methylcoumarin (DEVD-AMC; Enzo Life Sciences). The 
fluorescence was quantified at the start of the reaction and after 30 min. Protein concentrations 
were determined using CBQCA Protein Quantitation Kit (Life Technologies). Caspase activity 
was determined by dividing the change in fluorescence by total protein content of the reaction 
mixture. 
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5.3.6. Statistical analyses 
One-way analysis of variance (ANOVA) was used when comparing two groups with 
Tukey’s post hoc test. For more than two groups, two-way ANOVA was used with Bonferroni 
correct. Significance was calculated at an alpha of 0.05. 
 
5.4. Results 
5.4.1. ApcMin/+ IMCE cells exhibit microtubule defects 
Previous studies have shown localization of APC at the growing (plus) ends of 
microtubules and that APC mutations reduce the rate of microtubule polymerization in vitro 
[208, 242, 244]. We sought to characterize overall defects in microtubule morphology of 
ApcMin/+ heterozygous cells. We used a set of conditionally immortal cell lines derived from 
C57/BL6 mice, Apc+/+ Young Adult Mouse Colonocytes (YAMCs) and ApcMin/+ Immorto-Mouse 
Colonic Epithelial cells (IMCEs), developed by Dr. Robert Whitehead (Vanderbilt University, 
Nashville, TN). We immunostained YAMCs and IMCEs for β-tubulin to identify changes in 
microtubule structures. As shown in Figure 5.1A, Apc heterozygote IMCE cells show overall 
aberrations in microtubule networks. Generally, cells are more elongated and display 
microtubules network that are concentrated towards the periphery of the cell. Additionally, some 
cells lack partial or complete microtubule networks. Microtubules are highly dynamic during 
mitosis and require precise spindle assembly for proper chromosomal division. Interestingly, no 
gross microtubule abnormalities were observed in mitotic cells with regards to their mitotic 
spindles. 
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Figure 5.1. AK301 disrupts microtubule networks in both Apc+/+ YAMCs and ApcMin/+ 
IMCE cells. 
(A) Mouse colonocyte cell lines YAMCs and IMCEs were fixed, permeabilized, and 
immunostained for β-tubulin (red). Nuclei were counterstained with DAPI (blue). In general, Apc 
mutant IMCE cells exhibited spindle shape compared to a more rounded cell shape in Apc 
wildtype YAMCs (arrowheads). Moreover, IMCE cells showed disruption or lack or microtubule 
networks. (B) β-tubulin of AK301-treated YAMC and IMCE cells showed increased disruption 
of microtubule networks; cells exhibited peripheral staining for β-tubulin and mitotic cells lacked 
microtubule spindle assembly (arrowheads). 
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5.4.2. Apc mutant IMCE cells show multiple microtubule organizing centers (MTOCs) 
following AK301 treatment 
To determine if AK301would alter microtubule networks in YAMCs and IMCE cells, we 
stained treated cells with AK301 and immunostained them for β-tubulin. As shown in Figure 
5.1B, AK301 disrupted microtubule networks in both YAMCs and IMCE cells. Non-mitotic 
cells showed microtubule networks clustered at the periphery of the cells; mitotic cells showed 
peripheral microtubule networks, but no spindle assembly. Moreover, spindle-shaped IMCE cells 
appeared more circular in shape with peripheral microtubule staining. 
Previously, we showed that AK301-treated colon cancer cells showed multiple MTOCs. 
To determine if there were difference in microtubule organizing centers between Apc normal and 
Apc mutant cells, we treated YAMCs and IMCE cells with 100 nM of AK301 and stained with a 
centrosomal marker, aurora kinase A. Untreated cell mitotic YAMCs and IMCEs showed normal 
bipolar localization of aurora kinase A (Figure 5.2A). Treatment of Apc normal YAMCs showed 
aurora kinase A deposition at two foci. This localization is consistent with aurora kinase A 
association at the centrosome, where it is normally localized in mitotic cells. (Figure 5.2B, left 
panel). However, AK301 treatment of Apc mutant IMCE cells showed the formation of multiple 
diffuse foci for aurora kinase A (Figure 5.2B, right panel). The emergence of multipolar aurora 
kinase A centers in IMCE cells suggests that Apc mutant cells are more sensitive to the 
centrosome disruption or centrosome assembly. 
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Figure 5.2. AK301 induces the formation of multiple aurora kinase A foci in Apc mutant 
IMCE cells. 
(A) YAMCs and IMCE cells were immunostained for aurora kinase A (green). Nuclei were 
counterstained with DAPI (blue). Untreated YAMCs and IMCE cells show a bipolar localization 
of aurora kinase A in mitotic cells (cells with condensed chromosome morphology). (B) Aurora 
kinase A immunostaining of AK301-treated YAMCs and IMCE cells shows diffused and 
unsegregated localization of aurora kinase A in mitotic cells of both YAMCs and IMCE cells. 
Moreover, AK301 treatment of IMCE cells induced the formation of multiple diffused aurora 
kinase A foci. Inset shows a higher magnification of one representative IMCE cell treated with 
AK301. 
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5.4.3. ApcMin/+ IMCE cells are sensitive to AK301 treatment and undergo apoptosis in the 
presence of TNF 
To assess the sensitivity of Apc-mutant cells to a microtubule disrupting agent, we treated 
YAMC and IMCE cells with 200 nM and 400 nM of a novel and potent microtubule inhibitor, 
AK301, previously identified in our laboratory. Although AK301 induced caspase-3 activation in 
both Apc normal and Apc mutant cells, active caspase-3 was found to be about four times higher 
in Apc mutant IMCE cells compared to YAMCs (Figure 5.3A). To confirm that the cells were 
undergoing apoptosis, we perfomed Annexin V staining of YAMCs and IMCEs treated with 
AK301. As shown in Figure 5.3B, IMCE cells treated with AK301 showed increased Annexin V 
staining, suggesting that Apc mutant cells treated with AK301 are more susceptible to apoptosis, 
but not Apc normal cells. Previously, we provided evidence for the reversibility of AK301-
induced mitotic arrest and showed that cells exiting mitosis aberrantly underwent apoptosis more 
effectively. We hypothesized that AK301 would induce similar increase in apoptosis in IMCE 
cells compared to YAMC cells following AK301 removal. We treated the cells with AK301 and 
followed sub G1 population at 20, 30, and 40 hrs post mitotic release. Consistent with our results 
above, AK301 induced significantly greater apoptosis in IMCE cells compared to YAMCs 
(Figure 5.3C). More importantly, release from AK301 enhanced apoptosis in both YAMCs and 
IMCE cells, but the increase was significantly greater in IMCE cells at each time interval post 
mitotic release. 
Studies from our laboratory have demonstrated that pharmacological disruption of the 
rate of microtubule polymerization can result in enhanced death receptor trafficking, primarily 
TNFR1, to the cell surface [145, 193]. To determine the sensitivity of ApcMin/+ IMCE cells to 
TNF, we treated YAMC and IMCE cells with 50 ng/ml of TNF for 10 hrs and 20 hrs and 
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determined the levels of active caspase-3. As shown in Figure 5.3D, Apc-mutant IMCE showed 
significant activation of caspase-3 after 10 h and 20 h of treatment compared to YAMCs, 
suggesting the enhanced sensitivity of Apc-mutant cells to TNF. Interestingly, Apc wildtype 
YAMC cells showed a significant decline in active caspase-3 levels, suggesting a protective 
effect of TNF on these cells. Consistent with the role of TNF in inducing cell survival and cell 
death, these data suggest cell-specific dual function of TNF signaling – a protective function for 
normal cells and as an inducer of apoptosis for mutant cells. Together, these data indicate that 
Apc mutant cells exhibit morphological differences at the cellular level that can be targeted for 
elimination of mutant cells. 
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Figure 5.3. AK301 enhances the sensitivity of Apc mutant IMCE cells during mitosis and 
following mitotic release. 
(A) YAMCs and IMCE cells were treated with 200 and 400 nM of AK301 for 16 h. Cell lysates 
were prepared and tested for active caspase-3 by DEVD-AMC fluorogenic assay. AK301 
induced significantly high levels of caspase-3 activation in IMCE cells at both concentrations 
(*P < 0.0001). (B) Annexin V staining of YAMCs and IMCE cells showed a higher proportion 
of AK301-treated IMCE cells staining positive for Annexin V on the cell surface, indicating that 
IMCE cells are undergoing apoptosis in response to AK301 treatment. (C) YAMCs and IMCE 
cells were treated with AK301. Following treatment, AK301 was removed and cells were 
released from mitotic arrest. Cells were harvested at the indicated times and their DNA content 
was analyzed by flow cytometry. Analysis of the sub G1 population showed that release from 
AK301-induced mitotic arrest resulted in significantly greater sub G1 population in IMCE cells 
compared to their YAMC counterparts (*P < 0.0001). (D) Apc wildtype YAMCs and Apc 
mutant IMCE cells were treated with 50 ng/ml of TNF for 10 or 20 hrs. Cell lysates were 
prepared and analyzed for caspase-3 activation by DEVD-AMC assay. TNF induced 
138 
significantly higher caspase-3 activation in IMCE cells compared to untreated control cells (*P < 
0.0001). Interestingly, 20 hrs of TNF treatment showed a reduction in caspase-3 activation in 
YAMCs (*P < 0.0001), suggesting a protective role of TNF in wildtype cells. 
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5.4.4. Overexpression of C-terminus truncated APC and treatment with AK301 induces multiple 
MTOCs in HEK293 cells 
To assess if overexpression of the truncated APC would have similar effects on MTOCs 
to that in IMCE cells, we transiently transfected HEK293 cells with a truncated human APC gene 
(truncated at the same site as the Min mutant). This APC was fused to the 3’ end of Gfp in a 
pEFGP-C1 vector, under the control of CMV promoter. The resulting APCΔC protein was fused 
to GFP, which was used as a marker for screening cells with APCΔC. Figure 5.4 shows a 
schematic of the methodology used to generate APCΔC-GFP fusion protein. Using our 
transfection protocol (See Section 5.3.1), we obtained a transfection efficiency greater than 85 
percent (Figure A6A). We prepared whole protein extract from both GFP and APCΔC-GPF 
expressing cells and immunoblotted for the N-terminus of APC to confirm the expression of 
APC-GFP in HEK293 cells (Figure A6B). Immunostaining for aurora kinase A showed results 
similar to those obtained with YAMC and IMCE cells (Figure 5.4B). Untreated APCΔC-GFP 
cells showed diffused, bipolar localization of aurora kinase A; treatment with AK301 resulted in 
the formation of multiple, diffused aurora kinase A foci. Further, consistent with the 
YAMC/IMCE data, APCΔC-GFP expressing HEK293 cells are elongated with spindle-shaped 
microtubule networks. AK301 treatment disrupts the microtubule networks in both GFP and 
APCΔC-GFP cells (Figure 5.4C). These data, together with YAMC/IMCE data, suggest that C-
terminus truncating mutation of APC can affect aurora kinase A deposition and that treatment of 
APC mutant cells with AK301 results in aberrations in spindle assembly during mitosis. 
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Figure 5.4. AK301 induces the formation of multiple aurora kinase A foci in HEK293 cells 
overexpressing C-terminus truncated APC (APCΔC) 
(A) Schematic of the generation of GFP-tagged C-terminus truncated APC and generation of 
stable cell lines. Mutations were introduced in full length human APC gene by PCR and 
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confirmed by agarose gel electrophoresis and capillary electrophoresis. The truncated APC 
fragment was ligated into pEGFP-C1 vector at the 5’-end of Gfp. Cells were transfected using 
Lipofectamine 3000® reagent and selected for geneticin resistance. Cells were screened based on 
the GFP expression. GFP and APCΔC-GFP expressing HEK293 cells were treated with 100 nM 
of AK301 and immunostained for (B) aurora kinase A and (C) β-tubulin. (B) Untreated cells 
show bipolar localization of aurora kinase A. However, treatment with AK301 resulted in 
diffused multiple aurora kinase A foci (arrowheads). (C) Similar to Apc mutant IMCE cells, 
APCΔC-GFP expressing HEK293 cells exhibited spindle cell shape compared to GFP expressing 
HEK293 cells. Treatment with AK301 resulted in disruption of microtubule networks with a 
more peripheral tubulin staining. Moreover, microtubule disruption in APCΔC-GFP resulted in a 
more round shape, consistent with AK301-treatmetn of IMCE cells.  
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5.4.5. AK301 enhances apoptosis in cells with truncated APC 
To determine if overexpression of truncated APC conferred growth advantage in 
HEK293 cells, we followed the growth of transiently transfected HEK293 cells over 72 h. Cells 
were harvested and analyzed by flow cytometry. As shown in Figure 5.5A, APCΔC-GFP cells 
were significantly more sensitive to apoptosis after transfection, which was enhanced by up to 3-
fold by 24 hours post transfection. However, the apoptosis in truncated APC-expressing cells 
decreased over time with about 5 percent apoptotic events by 72 h. 
To assess the effect of AK301 treatment on truncated APC-expressing HEK293 cells, we 
treated transiently transfected HEK293 GFP and APCΔC-GFP cells with increasing 
concentrations of AK301 and analyzed the appearance of sub-diploid population by flow 
cytometry. AK301 induced a mitotic arrest in both cells, and a modest, but significantly greater 
arrest in APCΔC-GFP cells (data not shown). More importantly, AK301 significantly enhanced 
apoptosis in APCΔC-GFP, but not GFP expressing cells (Figure 5.5B). Moreover, the apoptotic 
response of APCΔC-GPF cells followed a dose response with an EC50 of about 45.2 nM with a 
95% confidence interval of 37.9 nM and 53.9 nM. Together with YAMC/IMCE data, these 
results indicate the APC mutant cells are sensitive to AK301-induced microtubule disruption 
readily undergo apoptosis. 
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Figure 5.5. AK301 enhances apoptosis in APCΔC-GFP expressing HEK293 cells in a dose-
dependent manner. 
(A) HEK293 cells were transiently transfected with APCΔC-GFP and GFP containing plasmids 
for 24 hrs. Cell were transferred to fresh medium and cell growth was followed for 72 hrs. Cells 
were harvested and stained with PI. Flow cytometric analysis of the sub G1 population showed 
significantly greater apoptosis in AK301-treated APCΔC-GFP cells (*P < 0.0001). (B) 
Representative dose-response curves of sub G1 population with increasing concentrations of 
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AK301. Significant sub G1 proportions were observed in APCΔC-GFP expressing HEK293 cells 
at all concentrations of AK301 (*P < 0.0001). EC50 of APCΔC-GFP expressing HEK293 cells 
was determined to ≈ 45 nM. 
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5.5. Discussion 
Mutations in APC are found in a majority of colon cancers and are considered to be the 
first mutations in colon tumorigenesis [203, 206]. Loss-of-function mutations in APC trigger a 
chain of molecular alterations that lead to colon tumorigenesis. We previously identified a class 
of small molecules that induced mitotic arrest in colon cancer cells and sensitized these cells to 
apoptosis by increasing the cell surface expression of death receptors [145, 193]. AK301 was the 
most potent compound identified in this class. In this study, we report that AK301 sensitizes 
untransformed APC mutant cells to apoptosis. Our data demonstrate that APC mutations, leading 
to reduced microtubule polymerization, renders a cell sensitive to spontaneous apoptosis or to 
death ligands, such as TNF. We further show that APC mutant cells are also sensitive to AK301-
induced microtubule disruption with an EC50 of ≈ 45 nM. Consistent with our previous studies, 
our results indicate that declustering of centrosomes may lead to an enhanced apoptotic response 
in mutant cells. To the best of our knowledge, our study is the first to describe an association 
between APC mutation status and cell sensitivity to a microtubule disrupting agent.  
APC plays an important role in microtubule polymerization at the plus ends and recruits 
end binding protein 1 (EB1) for stabilization of microtubule fibers [238, 239, 249]. The C-
terminus of APC contains domains for both microtubule and EB1 binding [250]. Consistent with 
the role of APC in microtubule polymerization, both ApcMin/+ and APCΔC-expressing HEK293 
cells showed aberrant microtubule shape (spindle-shaped microtubule fibers). Additionally, Apc-
mutant cells, occasionally, lacked microtubule networks, while exhibiting more peripheral 
localization of microtubules. This may be attributed to the role of microtubules in cortical 
anchoring and cell-cell adhesion, which is necessary for cell survival [251, 252]. Furthermore, 
mutations in APC have also been shown to upregulate EB1 during colorectal cancer (CRC) 
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progression to enhance the stability of microtubules during mitosis [253, 254]. A number of 
microtubule disrupting agents tested (e.g., vinca alkaloids and nocodazole), in vitro, target cells 
independent of APC mutation [255-257]. Therefore, targeting pathways that results in reduced 
microtubule stability and enhanced cell death signaling may lead to the development of specific 
and effective chemopreventive agents. 
Previously, we demonstrated that disruption of microtubule polymerization can enhance 
the cell surface expression of death receptors, such as TNFR1 [145]. This is consistent with our 
finding that Apc mutant IMCE cells were sensitive to cell death by TNF. We also showed that 
AK301 and other active derivatives induced the formation of multiple microtubule organizing 
centers (MTOCs) in colon cancer cells. In this study, we show that supernumerary centrosomes 
are an early step in colon carcinogenesis, following APC mutation. Centrosomes are the primary 
sites for microtubule organization, regulating cell shape, polarity, motility, and cell division 
[258, 259]; centrosome amplification is a common characteristic of various human cancers [157, 
159, 260, 261]. We propose that APC mutations result in over-duplication of centrosomes during 
synthesis phase of cell cycle. These centrosomes are then clustered into two foci to ensure proper 
segregation of the genome. Disruption of microtubules polymerization (e.g., AK301 and 
derivatives), without their complete abrogation (as in the case of vinca alkaloids), or centrosome 
declustering (e.g., bromo-noscapine, EM011 [262]) may be an effective way of targeting mutant 
cells for elimination. How APC mutations result in centrosome amplification and how 
declustering of centrosomes sensitizes cells to apoptosis requires further investigation. This may 
have implications in preventing colon cancer in patients at high risk for developing the disease. 
Akin to the role of APC in microtubule polymerization, APC is required for regulation of 
microtubule-kinetochore attachments, and thus, mitotic checkpoint [209]. Moreover, APC 
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interacts directly with mitotic checkpoint proteins, BUB1 and BUBR1, providing stable 
microtubule-kinetochore attachments [263]. Therefore, mutations in APC lead to dysfunctional 
mitotic checkpoint and may result in cells slipping from mitosis. This gives rise to chromosomal 
instability and results in tetraploidy in vivo. Tetraploidy has been correlated with poor cancer 
prognosis [235]. Genetic instability (or chromosomal instability) is not only cancer-promoting, 
but also tumorigenic [235, 264]. Consistent with our previous results with colon cancer cells, 
analysis of AK301-treated cells showed that AK301 arrested cells in mitosis. However, it should 
be noted that only APC mutant cells (both IMCE and APCΔC-GFP HEK293 cells) were prone to 
apoptosis, albeit mitotic arrest similar to APC normal cells. We propose that microtubule 
disruption by AK301 induces the formation of multiple MTOCs, activating mitotic checkpoint in 
an APC-independent manner. In light of our previous results, it is possible that disruption of 
microtubules by AK301 enhances death receptor signaling and aggregation of death receptors 
may activate caspase cascade, resulting in apoptosis.  
In summary, APC mutations result in genetic alterations and molecular aberrations that 
promote colon carcinogenesis. Our results shed light on the early molecular changes in colon 
cells following APC mutations. It is important to understand the mechanisms that undermine 
apoptosis and promote aberrant cell division. This could lead to development of novel, targeted 
therapies and chemopreventive agents for elimination of mutated cells from colon crypts. 
  
149 
CHAPTER 6 
CONCLUSIONS 
 
 Our initial work was focused on understanding how colon cancer cells survive their 
inflammatory micro-environment with high levels of death ligands, such as TNF. We identified a 
novel class of piperazine-based compounds that sensitized colon cancer cells to death ligands. 
Further studies on these compounds generated a more potent AK301 with EC50 of 115 nM and 
elucidated their role in mitotic arrest through disruption of microtubule polymerization and 
ligand-dependent apoptosis by increasing the surface expression of death receptors. Additional 
studies to understand the vulnerability of AK301-arrested cells indicated that activation of ATM 
and stabilization of p53 in the mitotically arrested cells were responsible for inducing apoptosis 
in mitotically arrested following their exit from the arrest. Furthermore, we showed that AK301 
was able to target APC mutant cells in vitro effectively in the absence of death ligands. Table 6.1 
summarizes the apoptotic inducing effects of AK301 treatment on different cell lines analyzed in 
this dissertation, both in the presence of TNF or following release from mitotic arrest. Table 6.2 
describes how patients with different types of colonic lesions would be predicted to respond to 
treatment with AK301. As shown in the table, mutations in APC and/or p53 are predicted to 
respond differently to AK301 and TNF. Over 80 percent of colorectal cancers have mutations in 
the APC tumor suppressor gene, most of which result in a truncated protein. Since APC mutant 
cells are more sensitive to AK301 treatment, we envision administration of AK301 would 
selectively target mutant cells for elimination. This targeting would be observed in initiated 
colon tissue that is still heterozygote for APC and would be accentuated in tissue environments 
with high levels of TNF, which is typically found in colon cancers. The activation of p53 would 
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play an important role in elevating apoptosis, particularly after AK301 levels have dropped 
following excretion. Approximately 50 percent of all colorectal cancers express wildtype p53 
and AK301-induced apoptosis would be high in these tumors after Ak301 levels drop and cells 
are released from arrest. In general, our data suggest that colon cancers with a mutated APC gene 
and a wildtype p53 gene would be most sensitive to AK301 treatment due to a combined effect 
of p53-induced apoptosis and by extrinsic apoptosis by TNF in the tumor microenvironment. 
 There are two general classes of colon cancers—those showing chromosomal instability 
and those with a hypermutator phenotype. Hypermutated cancers, which represent ~20% of 
colon cancers, are usually p53-normal, but about half of the hypermutated cancers have APC 
mutant [40]. Based on these statistics, we predict that AK301 could potentially provide a 
significant therapeutic benefit to ~10% of colon cancer patients. 
Overall, mutations in colorectal cancers result in molecular alterations that may be 
targeted with specificity and more effectively. Moreover, understanding the ways in which 
cancer cells take advantage of APC mutations will provide insight into pathways that promote 
tumorigenesis. In these studies, we explore the critical regulation of microtubule spindle 
formation and mitotic checkpoints by APC, identify small molecule agents that target APC 
mutant and colon cancer cells with more specificity. 
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Table 6.1. AK301-induced apoptosis in different cell lines in the absence or presence of 
TNF 
Cell type 
Mutation status Apoptosis with AK301 
APC TP53 - TNF + TNF 
YAMC or GFP HEK293 
(normal) +/+ +/+ Low Low 
HT29 -/- -/- Low High 
HCT116 +/+ +/+ High High 
HCT116 p53-/- +/+ -/- Low - 
IMCE -/+ +/+ High High 
APCΔC-GFP HEK293 -/+ +/+ High - 
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Table 6.2. Predicted effects of AK301-induced mitotic arrest and release from mitotic 
arrest on different colon tumor types 
Tissue type Mutation status AK301 treatment AK301 excretion 
Cancer 
(hypermutated) APC
-/- TP53+/+ Mitotic arrest, High TNF, High apoptosis Highest apoptosis 
Cancer 
(hypermutated) APC
+/+ TP53+/+ Mitotic arrest, High TNF, High apoptosis High apoptosis 
Cancer 
(chromosomal 
instability) 
APC-/- TP53-/- Mitotic arrest, High TNF, High apoptosis 
Continuing mitotic arrest, 
Residual apoptosis 
Initiated APC-/+ TP53+/+ Mitotic arrest, Low TNF, Moderate apoptosis 
Completion of mitosis, 
Moderate apoptosis 
Normal APC+/+ TP53+/+ Mitotic arrest, Low TNF, low apoptosis 
Completion of mitosis, 
Low apoptosis 
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6.1. Enhancing apoptosis in colon cancer cells 
 Immune and inflammatory cells frequently infiltrate colon cancer cells and early colonic 
lesions [75, 265, 266]. Even though inflammatory cytokines have anti-tumor activity, chronic 
inflammation can promote cancer progression through the production of growth stimulating 
factors and DNA-reactive metabolites [267, 268]. We identified AK301 and its analogs that 
sensitized colon cancer cells to death ligands without significantly affecting cell survival. These 
compounds induced mitotic arrest in cancer cells and apoptosis in the presence of the death 
ligands. We showed that cellular sensitivity to the death ligands was primarily due to increased 
death receptor expression on the cell surface. These compounds (especially our most potent 
compound, AK301), are therefore, particularly useful in activating apoptotic signaling and 
sensitizing colon cancer with high levels of inflammatory signaling. 
 Structure-activity relationship studies revealed that AK301 and its analogs reduced the 
rate of microtubule polymerization in contrast to agents that induced greater disruption of 
microtubules. This reduced polymerization (over abrogation) may play a role in death signal 
trafficking on microtubule networks. One possible explanation is that AK301 alters microtubule 
networks in a way that the death receptors can be delivered to the cell surface more efficiently, 
but their removal is hindered. 
Furthermore, studies to understand the mechanism of AK301 showed that mitosis-to-
apoptosis transition requires exit from mitosis. Interestingly, we found that AK301 treatment and 
withdrawal was sufficient to induce apoptosis in p53-normal colon cancer cells. AK301 arrest 
induced high levels of activated ATM, which stabilizes p53, resulting in apoptosis. Some studies 
suggest that ATM activation, by itself, may target the activation of death receptors and caspase-8 
[269, 270]. Activation of ATM signaling was not observed with other agents that abrogated 
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microtubule polymerization. How AK301-induced mitotic arrest results in ATM signaling is 
unclear. 
Overall, our studies suggest that cancer cells can be sensitized to undergo apoptosis and 
understanding the mechanisms that reactivate apoptotic processes in cancer cells can lead to the 
development of targeted chemotherapeutic agents. 
 
6.2. Targeting mutant, non-transformed colon cells with AK301 
 The five-year survival rate for stage I colon tumors is 90 percent [2, 5]. Unfortunately, 
less than 40 percent of colon tumors are detected at an early stage; the five-year survival rate 
drops rapidly with each subsequent stage of colon cancer [1, 2]. Moreover, 30-50 percent of the 
patients undergoing curative resection for colon cancer have recurrent disease [5]. Besides early 
diagnosis and accurate staging of colon cancer patients, there is a need to identify new 
chemopreventive agents to reduce the risk of colon cancer in at-risk patients. Studies indicate 
that mutated cells of the colonic crypt as well as early lesions exhibit molecular differences due 
to APC and other mutations [203, 229, 239, 250]. These differences may be exploited, such as 
with AK301, to target mutated cells, making them vulnerable to cell death, thereby reducing the 
risk of developing colon tumors. We envision AK301 interfering with microtubule 
polymerization in a manner similar to mutated APC. This disruption may accentuate mitotic 
arrest at a state that activates ATM signaling. Whether these compounds can be used for this 
application remains to be determined. 
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6.3. Future directions 
 Our studies identified novel compounds that sensitize APC mutant (non-transformed) 
cells and colon cancer cells to apoptosis through a mitotic-to-apoptotic transition of the exiting 
arrested cells. In our previous studies, we showed that the positioning of chloride group on 
phenyl and ethoxy group on benzoyl groups on the piperazine core were required for the activity 
of these compounds. Currently, further structure-activity relationship studies are underway to 
modify these side groups develop more potent compounds that can robustly and specifically 
transition cancer cells into apoptosis. Moreover, new generation of compounds will feature 
probes that will aid in target identification and the mechanism of action in more detail. 
All of the studies have been carried out in in vitro systems using either cancer cell lines or non-
transformed cells. Although these systems provide a cost and time effective method for screening 
and development of new agents, it is challenging to extrapolate in vitro results in vivo. Our near-
future goals are to determine the effect of these agents in Apc mutant and xenograft mouse 
model, assessing the effect of AK301 on survival and tumor volumes in mice. 
 
 In summary, current clinical diagnosis and treatment of colon cancer demands new 
approaches for prevention and treatment of colon cancer. A move towards individualized 
approach to treatment could yield better outcomes. Our studies provide evidence that APC 
mutations could result in cytoskeletal aberrations in the colonic cells that can be targeted 
effectively, reducing the risk of disease progression. Moreover, our studies provide a paradigm 
for targeting mitotic spindle defects and mitotic checkpoint with small molecule agents. Further 
development of pharmacological agents for specific targets will help in detailed understanding of 
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the processes at play in mutated cells and aid in the identification of novel chemopreventive and 
chemotherapeutic agents. 
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APPENDIX A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1. Structures of active compounds from the screen. 
Structures of the compounds selected out of a screen of 400 compounds from ChemBridge 
DIVERSetTM library of compounds. These compounds showed the highest levels of caspase-3 
activity as suggested by the percentage of cells expressing cleaved caspase-3. The respective 
IUPAC names of these compounds are listed. 
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Figure A2. Structure-specific requirement for TNF sensitization of colon cancer cells. 
(A) Structural analogs of AK3 and AK10 (AK20-AK24) were prepared with modifications to the 
benzoyl group and tested for TNF-sensitizing activity. Modifications included removal of 
benzoyl groups (AK20), substitution with tert-butyl (AK21), benzo[1,3]dioxol-5-yl (AK22), 
phenyl (AK23), and pyridine-4-yl (AK24). (B) Ht29 cells treated with analogs in (A) at 25 µM 
174 
and tested for their ability to enhance caspase-3 activation in a TNF-dependent manner using the 
DEVD-AMC cleavage assay. AK3 and AK24 induced significantly higher caspase activity than 
the other compounds tested (ANOVA, Tukey’s post-doc). (C) Dose-dependent caspase 
activation with AK3 and AK24 in the presence or absence of TNF was determined using the 
DEVD-AMC substrate. AK3 was significantly more active than AK24 at lower concentrations 
(*P < 0.05, **P < 0.01) 
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Figure A3. Structures of compounds that alter microtubule dynamics. 
Colchicine, nocodazole, and vinca alkaloids (vincristine and vinblastine) are microtubule 
destabilizers, whereas paclitaxel acts to stabilize microtubules. 
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Figure A4. Validation of AutoDock Vina for molecular docking study. 
(A) Colchicine, and (B) vinblastine were removed from their respective PDB structures and 
docked back into tubulin. The lowest energy structural poses obtained from docking were 
compared to that of the published poses. Both colchicine and vinblastine docked to their 
respective site with similar poses. (C) Lowest energy poses of AK3, AK301, and AK303. All 
three compounds bind in the same site on tubulin with similar poses. 
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Figure A5. AK301-treated HCT116 cells show activation of γH2AX, but not other mitotic 
arresting agents. 
p53+/+ HCT116 colon cancer cells were treated with 500 nM of the indicated mitotic arrest 
agents. Cells were then fixed and stained for γH2AX and PI as counterstain for DNA. Cells were 
analyzed by flow cytometry. Analysis was performed on cells that stained positive for PI. (B) 
Quantification of the flow cytometric data in (A). All agents induced γH2AX activation to some 
extent (*P < 0.05), but AK301-treated induced a significantly higher (15-fold) (**P < 0.0001) 
activation of γH2AX. 
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Figure A6. Expression of APCΔC-GFP in HEK293 cells with high transfection efficiency. 
(A) HEK293 cells were transiently transfected with GFP or APCΔC-GFP containing plasmid 
using Lipofectamine® 3000 Reagent for 24 hrs. Cells were harvested and analyzed by flow 
cytometry. Transfection of HEK293 cells yielded high transfection efficiencies (> 80%). (B) 
Protein extracts from transiently transfected APCΔC-GFP and GFP were prepared using RIPA 
protein extraction protocol. The lysates were run on polyacrylamide gels, transferred to a 
nitrocellulose membrane and immunoblotted for N-terminus of APC. APCΔC-GFP HEK293 
showed the expression of truncated APC-GFP fusion protein. 
 
